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ABSTRACT 
 
Bovine viral diarrhoea virus (BVDV) is the causative agent of a complex of 
disease syndromes in cattle with high economical and welfare impacts. BVDV 
occurs as two biotypes; cytopathic (BVDVcp) and noncytopathic (BVDVncp) 
determined by differential effects on cultured cells and can also be divided into 
two genotypes (BVDV1 and BVDV2) on the basis of genomic diversity. The 
interaction between BVDV and the host’s immune system is regarded a key 
aspect in the sequel of BVDV infection. Infection with BVDV normally causes an 
acute transient infection, with mild to subclinical signs, but occasionally results in 
severe and even fatal disease. More importantly, BVDVncp virus can cause 
persistent infections, evading both the adaptive immunity as well as important 
mechanisms of the innate immunity. In the present study, attempts were made to 
compare the effect of a BVDVncp infection on bovine monocyte-derived 
dendritic (mDCs) cells on their ability to produce IFNα/β, IL-10 and IL-12. To 
potentially assess strain-variabilities, two different type 1 BVDVncp strains were 
used, one associated with mild acute disease and the other one with severe acute 
disease. This study confirms previously published data demonstrating that mDCs 
are susceptible to BVDVncp infection which implicates the potential of 
BVDVncp to affect the functions of this important antigen presenting cell. 
Unfortunately no conclusive data was obtained from quantitative polymerase 
chain reaction for mRNA expression levels of IL-10 and IL-12. Production of 
IFNα/β was measured in supernatants from stimulated mDCs and consistent with 
existing data no notable levels of IFNα/β could be detected. To further investigate 
how BVDVncp interact with the IFNα/β response in mDCs, protein levels of the 
transcription factors interferon regulatory factor 3 (IRF3) and interferon 
regulatory factor 7 (IRF7) were investigated by Western blotting. Here, the strain 
causing a more severe disease form seemed to be able to interfere with IRF3 
protein levels differentially compared to the strain inducing a mild disease form. 
Thus, the data indicate that BVDVncp may interact in more than one way with the 
IFNα/β pathway, potentially by inhibiting IRF3 activity, and that these differences 
could be strain-specific and potentially linked to disease severity.  
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SAMMANFATTNING 
 
Bovint virus diarré virus (BVDV) orsakar ett komplext sjukdomssyndrom hos 
boskap världen över med stora ekonomiska förluster och negativ inverkan på 
djurvälfärden som följd. BVDV delas in i två biotyper, cytopatogen typ och icke-
cytopatogen typ (BVDVcp/BVDVncp). Detta är grundat på virusets effekt på 
celler odlade i cellkultur.  Viruset kan även delas in i genotyper, BVDV1 och 
BVDV2, baserat på genomisk diversitet. Interaktionen mellan BVDV och värdens 
immunförsvar är avgörande för infektionens slutresultat. BVDV orsakar vanligen 
en akut, övergående infektion med inga eller milda kliniska symtom men kan i 
vissa fall orsaka allvarlig sjukdom med dödlig utgång. BVDVncp kan även orsaka 
persisterande infektioner där viruset undviker upptäckt och eliminering av värdens 
immunförsvar. I denna studie utfördes försök för att undersöka effekterna av 
BVDVncp infektion på bovina monocytderiverade dendritiska celler (mDC) med 
avseende på produktion av IFNα/β, IL-10 och IL-12. För att utröna potentiella 
skillnader mellan stammar jämfördes två BVDV1ncp stammar, den ena associerad 
med milda sjukdomssytom vid akut infektion och den andra associerad med 
allvarliga akuta sjukdomssymtom. Denna studie konfirmerar tidigare publicerade 
data som visar att mDC är mottagliga för infektion av BVDVncp vilket innebär att 
viruset potentiellt sett skulle kunna påverka funktionen hos denna viktiga antigen 
presenterande cell. Olyckligtvis erhölls inga konklusiva data från kvantitativ PCR 
för IL-10 och IL-12. Produktion av IFNα/β undersöktes i supernatanter från 
stimulerade mDC och i linje med tidigare publicerade resultat kunde inget IFNα/β 
uppmätas. För att ytterligare utforska hur BVDVncp interfererar med 
produktionen av IFNα/β undersöktes proteinnivåer av transkriptionsfaktorerna 
interferon regulatory factor 3(IRF3) och 7 (IRF7) med Western blot. Resultaten 
visar att virusstammarna interagerar olika med IRF3 och att det virusisolat som 
förknippas med allvarliga sjukdomssymtom ger ökade proteinnivåer av IRF3 i 
mDC. Detta indikerar att BVDVncp kan interferera med IFNα/β-signalvägen på 
mer än ett sätt, potentiellt genom att blockera aktiviteten hos IRF3 och att dessa 
skillnader kan vara stamspecifika med en potentiell koppling till 
sjukdomsframkallande förmåga. 
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ABBREVIATIONS 
 
Ab- Antibody 
ACD-buffer- Acid Citrate Dextrose 
APC- Antigen Presenting Cell 
B- cell- B lymphocyte 
BVDV- Bovine Viral Diarrhoea Virus 
BVDVcp- Bovine Viral Diarrhoea Virus cytopathogenic biotype 
BVDVncp- Bovine Viral Diarrhoea Virus non cytopathogenic biotype 
BDV- Border Disease Virus 
BSA- Bovine Serum Albumine 
CAT- Chloramphenicol Acetyl Transferase 
CD- Cluster of Differentiation 
cDC- conventional Dendritic Cell 
cDNA- complementary Deoxyribonucleic Acid  
CSFV- Classical Swine Fever Virus 
Cp- Cytopathogenic 
CpG- Cytosine-phosphodiester bond- Guanosine 
CpG- ODN- Cytosine-phosphodiester bond- Guanosine Oligodeoxynucleotides 
DC- Dendritic Cell 
DMEM- Dulbecco's modified Earl's medium 
DNA- Deoxyribonucleic Acid  
dNTP- Deoxyribonucleotide Triphosphates 
ds- double stranded 
dsRNA- double stranded Ribonucleic Acid 
DTT- dithiothreitol 
eIF2- eukaryotic translation-Initiation Factor 2 
ELISA- Enzyme Linked Immunosorbant assay 
FACS- Fluorescent Activated Cell Sorting 
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FBS- Foetal Bovine Serum 
FSC- Forward Scatter 
GADPH- Glyceraldehyde-3-phosphate dehydrogenase 
GI-tract- Gastro Intestinal tract 
GM-CSF- Granulocyte-Macrophage Colony-Stimulating Factor 
HCV- Hepatitis C virus 
HS- Haemorrhagic Syndrome  
IAH- Institute of Animal Health 
IL-1β- Interleukin 1β 
IL-4- Interleukin 4 
IL-10- Interleukin 10 
IL-12- Interleukin 12 
IFA- Immunofluorescent assay 
IFN- Interferon 
IFNR-Interferon Receptor  
IκB- Inhibitor of NFκB 
IKK- Inhibitor of NFκB Kinase  
IPX staining- Immunoperoxidase staining 
IRAK- Interleukin-1 Receptor-Associated Kinase 
IRF- Interferon Regulatory Factor 
ISGF3- Interferon Stimulated Gene Factor 3  
ISG- Interferon Stimulated Genes  
ISP-1- Interferon-β Promoter Stimulator-1 
ISRE- Interferon Stimulated Response Element 
JAK1- Janus Kinase 1 
LDL-R- Low Density Lipoprotein Receptor 
MACS- Magnetic Activated Cell Sorting  
MDA5- Melanoma-Differentiation-Associated gene 5  
MDBK- Mardin-Darby Bovine Kidney cells  
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MDBKt2- Transfected Mardin-Darby Bovine Kidney cells 
MEM- Modified Earl’s Media 
mDC- monocyte derived Dendritic Cell 
MAPK- Mitogen Activated Protein Kinase 
MD- Mucosal Disease 
MHC- Major Histocompatibility Complex 
mRNA- messenger Ribonucleic Acid 
MOI- Multiplicity of Infection 
Mx- Myxovirus resistance gene 
Ncp- Non cytopathogenic 
NFκB- Nuclear Factor kappa B  
NK-cell- Natural Killer cell 
NRS- Normal Rabbit Serum 
OAS- 2’5’-Oligoadenylate Synthetase 
OD- Optical Density 
ODN- Oligodeoxynucleotides 
ORF- Open Reading Frame 
PAMP- Pathogen Associated Molecular Pattern  
PBMC- Peripheral Blood Mononuclear Cell 
PBS- Phosphate Buffered Saline 
PBS-T- Phosphate Buffered Saline- Tween 
PCR- Polymerase Chain Reaction 
pDC- plasmacytoid Dendritic Cell 
Pen/Strept- Penicillin/Streptomycin 
P.I.- Post Infection 
PI- Persistently Infected 
PKR- Protein Kinase R 
Poly(I:C)- Polyinosinic:polycytidylic acid 
PRRs- Pattern Recognition Receptor 
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qPCR- quantitative Polymerase Chain Reaction 
rbo- recombinant bovine 
rhu- recombinant human 
RIG-1- Retinoic-acid-inducible Gene I 
RIP1- Receptor Interacting Protein 1 
RNA- Ribonucleic Acid 
RPLPO- Ribosomal Protein Large PO 
RT- Room Temperature 
RVC- Royal Veterinary College 
SD- Standard Deviation 
SDS-Sodium Dodecyl Sulfate 
SDS-PAGE- Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
ss- single stranded 
SSC- Side Scatter 
STAT- Signal Transducer and Activator of Transcription  
T-cell- T lymphocyte 
TBK1- TRAF-family-member-associated NFκB activator Binding Kinase 1 
Th-cell- T helper cell 
TIR-domain- Toll/Interleukin-1 Receptor domain 
TNFα- Tumour Necrosis Factor α 
TRAF6- Tumour necrosis factor Receptor-Associated Factor 6 
TRIF- TIR domain-containing adapter inducing IFN  
TLR- Toll-Like Receptor 
TYK2- Tyrosine Kinase 2  
UK- United Kingdom 
USA- United Sates of America 
5’UTR- 5’ Untranslated Region 
WB- Western Blot 
WNV- West Nile Virus 
13 
 
INTRODUCTION 
 
1.1 Bovine viral diarrhoea virus (BVDV) 
BVDV is an endemic viral disease affecting both economical and welfare aspects 
of the cattle industry globally. Despite major control efforts this disease continues 
to cause problems, mainly due to the ability of BVDV to cause persistent 
infections (Houe 1999). The way BVDV interacts with the innate immune system 
is critical both for the pathogenesis of the BVDV disease complex and for the 
development of immunity. Knowledge of these processes is absolutely vital when 
it comes to developing efficacious vaccines.  
1.1.1 Classification and characterisation 
BVDV belongs to the genus Pestivirus within the family Flaviviridae (Table 1.1). 
BVDV has a single stranded positive sense ribonucleic acid (ssRNA) genome 
approximately 12.5 Kb in length with a single open reading frame (ORF). The 
genome is translated to a polyprotein which is cleaved into individual viral 
proteins by host cell and viral proteases (Figure 1.1) (Meyers and Thiel 1996). 
The virus replicates in the cytoplasm and obtains the outer envelope from host 
membranes before being released by exocytosis (Ridpath and Goyal 2005).  
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Tabel 1.1 Taxonomy of the Flaviviridae family 
Family Genus Virus of importance 
to veterinary 
medicine* 
Virus of importance 
to human medicine* 
Flaviviridae    
 Pestivirus   
  Bovine viral 
diarrhoea virus 1 
(BVDV1) 
Bovine viral 
diarrhoea virus 2 
(BVDV2) 
 
  Classical swine 
fever virus 
(CSFV) 
 
  Border disease virus  
  (BDV)  
 Flavivirus    
  Louping ill virus Tick borne 
encephalitis virus 
  West Nile virus 
(WNV) 
Dengue virus 
  Japanese 
encephalitis 
Yellow fever virus 
 Hepacivirus   
   Hepatitis C virus 
(HCV) 
    
Taxonomy of the Flaviviridae family (adapted from the database of the International 
Committee on Taxonomy of Viruses http://www.ncbi.nlm.nih.gov/ICTVdb/). * Not a 
complete list for the genus Flavivirus which contains a number of arthropod borne 
viruses causing important diseases, many with zoonotic potential. 
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5’ 
 
 
 
3’ 
Figure 1.1 Organisation of the BVDV genome (adapted from Meyers and Thiel 1996). 
The structural proteins building up the virion are the nuclocapsid protein C and the 
envelope associated glycoproteins E
rns
, E1 and E2 (Meyers and Thiel 1996). E2 is the 
major target for neutralizing antibodies resulting in protective immunity (Bolin and 
Ridpath 1996 and Bruschke et al 1997). The nonstructural proteins governing viral 
functions are N
pro
, P7, NS2-3, NS4A, NS4B, NS5A and NS5B. In the cytopathic biotype of 
BVDV NS2-3 is cleaved and NS3 is expressed alone at the same level as NS2-3. This 
makes NS3 a marker for BVDVcp (Meyers and Thiel 1996).  
 
The cellular receptor for BVDV is thought to be ubiquitously expressed, such as 
CD46 or the low density lipoprotein receptor (LDL-R), with uptake mediated by 
clathrin coated pits (Agnello et al 1999, Maurer et al 2004, Blanchard et al 2006).  
1.1.1.1 Genotypes  
Genomic and antigenic diversity is well documented among BVDV isolates. 
BVDV is divided into two genotypes; BVDV1 and BVDV2 on the basis of 
phylogenetic studies of the 5’ untranslated region (5’ UTR) (Figure 1.2) (Ridpath 
et al 1994). BVDV1 is predominant in the UK but BVDV2 has been isolated 
(Wakeley et al 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
       N
pro
 C    E
rns
    E1     E2   p7   NS2                NS3          NS4A     4B             NS5A                     5B 
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Flaviviridae 
Pestivirus 
BVDV 
 
BVDV1                                       BVDV2 
 
 
cp and ncp                                 cp and ncp 
Figure 1.2 Schematic illustration of the general categorisation of bovine viral diarrhea 
virus. BVDV can be subdivided into two genotypes; BVDV1 and BVDV2 (in each of these 
genotypes further subdivision can be made, 11 subgenotypes have recently been 
described within BVDV1 (Vilcek et al 2001). Regardless of genotype BVDV also exists in 
two different biotypes; non-cytopathogenic (ncp) or cytopathogenic (cp). 
 
1.1.1.2 Biotypes 
All pestiviruses occur in two different biotypes depending on their ability to either 
induce visible cytopathic cell death or not: the former is the cytopathogenic 
biotype (BVDVcp) whilst the other is the non-cytopathogenic biotype 
(BVDVncp). The molecular basis remains to be elucidated. At the molecular 
level, BVDVcp but not BVDVncp cleaves NS2-3 to produce NS3 which can be 
used as a marker for infection (Meyers and Thiel 1996, Kümmerer et al 2000). 
1.1.2 The Disease spectrum 
BVDV is responsible for a complex of diseases in cattle ranging from mild 
transient acute infections to fatal mucosal disease. The different aspects of the 
disease and the main concepts of the pathogenesis revealing the interesting nature 
of this virus have been reviewed by many (Stöber 1984, Radostits and Littlejohns 
1988, Brownlie 1991, Brownlie et al 2000). Clinical disease can be divided into 
acute disease, in utero infection and mucosal disease (MD) (Figure 1.3).  
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                                                      BVDV all genotypes 
 
 
          Acute disease                       In utero infections           Mucosal disease (MD)  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Overview of the BVDV disease complex (Stöber 1984, Radostits and 
Littlejohns 1988, Brownlie 1991, Brownlie et al 2000) 
 
1.2 Recognition of viral infection by the innate immune system 
One way in which viral infection can be detected by the innate immune system is 
through pattern recognition receptors (PRRs) recognizing pathogen associated 
molecular patterns (PAMPs). Recognition of PAMP by PRRs activates cellular 
signalling resulting in production of pro-inflammatory cytokines and interferon-
α/β (IFNα/β also known as type I interferon) but also maturation of dendritic cells 
(DCs). PRRs can be classified into several families. One such family is the toll-
like receptor (TLR) family which consists of membrane bound receptors primarily 
present in immune cells but also in other cell types like epithelial cells. Virus 
infection can also be sensed by cytosolic receptors such as the RIG-I-like family 
and the IFNα/β inducible protein protein kinase R (PKR) (Haller et al 2007, 
Hornung et al 2008). 
1.2.1 TLRs 
Expression of TLRs varies dependent upon the cell subset and in some cases 
stimulation. Some TLRs are more ubiquitously expressed whereas other TLRs can 
be restricted to one cell type (Janssens and Beyaert 2003). Up to 14 TLRs 
(Werling and Coffey 2007) have been described in different species and those with 
known functions can be divided into two main groups; TLRs recognizing PAMPs 
made up by lipids and TLRs recognizing PAMPs made up by nucleic acid (Brikos 
and O’Neill 2008).  
Viruses exploit the cellular machinery for their replication and dissemination thus 
lacking many PAMPs, therefore detection is dependent upon recognition of viral 
nucleic acids. So far TLR3, 7, 8 and 9 (Table 1.2) have been described to be 
involved and are strategically located on the endosomal membrane utilising a 
common route of viral infection through the endosomal pathway.  
Transient infections are 
often mild but can include 
clinical signs as agalactia and 
diarrhoea. BVDV2 is 
generally associated with 
the more severe outcomes 
of acute BVDV infections. 
This includes haemorrhagic 
syndrome (HS) characterized 
by thrombocytopenia and 
high mortality. 
 
BVDVncp infections of the 
seronegative pregnant dam 
can, dependent on the 
developmental stage of the 
foetus, result in abortions, 
congenital malformations or 
the birth of a persistently 
infected calf (PI). PI animals 
are viremic for life and lack 
virus specific antibodies. 
MD is an inevitably fatal 
disease associated with 
mucosal erosions in the GI 
tract, especially severe in 
association with lymphoid 
tissue like Peyer’s Patches. 
MD arises when a PI animal 
(usually between 6-18 
months of age) gets 
superinfected with a cp virus 
homologous with the 
persistent ncp virus.  
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Table 1.2 Toll-like receptors sensing viral nucleic acid 
Toll like receptor Ligand General expression 
 
TLR3 Viral dsRNA and the 
synthetic dsRNA mimic 
Poly(I:C) 
The cell membrane or 
endosomal membrane 
depending on cell type and 
species 
TLR7 and TLR8 ssRNA and synthetic 
imidazoquinoline-like 
molecules imiquimod 
(R-837) and resiquimod (R-
848) 
The endosomal membrane 
in immune cells 
TLR9 Unmethylated CpG 
sequences in DNA and 
synthetic CpG-ODN 
The endosomal membrane 
in plasmacytoid dendritic 
cells, species dependent  
Overview of toll like receptors (TLR) involved in viral recognition, their ligand specificity 
and general expression pattern in the human and murine system (Alexopoulou et al 2001, 
Gorden et al 2005, Kawai and Akira 2006, Barton 2007, Müller et al 2008) Poly (I:C): 
Polyinosinic:polycytidylic acid, CpG-ODN: Cytosine-phosphodiester bond- Guanosine 
Oligodeoxynucleotides 
 
TLR3 not only recognises viruses with a double stranded RNA (dsRNA) genome 
but also ssRNA viruses since dsRNA intermediates are produced during 
replication. TLR9 recognises unmethylated CpG sequences in DNA which occur 
in a much higher frequency in bacterial and viral DNA in comparison to 
vertebrate DNA. TLR7 and TLR8 are stimulated by ssRNA viruses but what 
motifs they recognise is unknown (Alexopoulou et al 2001, Kawai and Akira 
2006, Barton 2007, Müller et al 2008). 
1.2.1.1 TLR signalling  
Cellular signalling is generally very complex with different pathways being 
integrated or connected, therefore TLR signalling still contains aspects yet to be 
discovered, however this has been reviewed recently (Kawai and Akira 2006, 
Brikos and O’Neill 2008, Randall and Goodbourn 2008). 
Ligand binding to its specific TLR induces receptor dimerisation bringing 
together a TLR/IL-1 (TIR) signalling domain capable of binding adaptor proteins 
MyD88 or TRIF relaying the signal intracellularly towards the nucleus, ultimately 
activating various transcription factors including NFkB, and ATF2/c-Jun complex 
(Figure 1.4)(Brikos and O’Neill 2008). These transcription factors are central in 
regulating expression of pro-inflammatory cytokines such as IL-6, IL-1β, TNFα 
and IL-12. Signalling through TLRs also activate interferon regulatory factors 
(IRFs), mainly IRF3 and IRF7, which along with NFkB and ATF2/c-Jun regulate 
transcription of IFNα/β allowing an anti-viral state to be created (Kawai and Akira 
2006). The TLRs’ involvement in induction of IFNα/β expression and induction 
of DC maturation is of utmost importance in the antiviral immunity (Parker et al 
2007, Barton 2007).  
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Figure 1.4 Schematic representation showing an outline of TLR-signalling pathways 
(adjusted from Kawai and Akira 2006, Randall and Goodbourn 2008,  Brikos and 
O’Neill 2008) MyD88 is used as an adaptor by the IL-1 receptor and most TLRs except 
TLR-3. Binding of MyD88 to the receptor leads to employment of interleukin-1 receptor-
associated kinases (IRAKs) which bind tumour necrosis factor receptor-associated factor 
6 (TRAF6) to the receptor signalling complex. IRAKs and TRAF-6 will activate interferon 
regulatory factor 7 (IRF7) which translocates to the nucleus to stimulate IFNα/β 
production. TRAF6 interacts with an additional complex consisting of TAK1-binding 
proteins (TAB2/3) and transforming growth factor-β-activated kinase 1 (TAK1). TAK-1 is 
the key kinase passing on the phosphorylation cascade to the inhibitor of NFκB kinase 
(IKK) complex. This complex phosphorylates inhibitor of NFκB (IκB) leading to 
degradation of this protein and dissociation from nuclear factor-kappaB (NFκB). 
Subsequently NFκB translocates to the nucleus and stimulates transcription of 
proinflammatory cytokines. In addition to activatining IKK TAK-1 also activates the 
mitogen activated protein kinase (MAPK) cascade which results in activation of AFT-2/c-
Jun, transcription factors stimulating expression of IFNα/β and pro-inflammatory 
cytokines.  
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In TLR3 signalling the adaptor protein TIR domain-containing adapter inducing IFN 
(TRIF) is employed instead of MyD88. To transmit the stimulatory signal TRIF binds a 
kinase called TRAF-family-member-associated NFκB activator binding kinase 1 (TBK1). 
TBK1 activates interferon regulatory factor 3 (IRF3) and a homologue to IKK named 
IKKε. NFκB activation via TLR3 requires assembly of TRAF6 and receptor interacting 
protein 1 (RIP1) to recruit the IKK complex. 
 
1.2.2 Cytosolic receptors sensing dsRNA 
TLR expression is limited dependent upon cell type, however all cells have the 
ability to sense and respond to dsRNA via cytosolic receptors (Figure 1.5). RIG-1 
and MDA5 are ubiquitously expressed receptors which activate NFkB and IRF3 
and IRF7 upon binding dsRNA resulting in the transcription of IFNα/β and pro-
inflammatory cytokines (Meylan et al 2006, Randall and Goodbourn 2008). 
Interferon inducible protein kinase R (PKR) is activated by dsRNA resulting in 
further amplifying IFNα/β production and the shut down of protein synthesis 
through the inactivation of protein translation initiation factor eIF2 (Kumar et al 
1994, Zamanian-Daryoush et al 2000).  
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Figure 1.5 Different intracellular receptors sensing dsRNA (adapted from Haller 2007). 
Retinoic-acid-inducible gene I (RIG-I)-I and melanoma-differentiation-associated gene 5 
(MDA5) elicit activation of NFκB and IRF3 and IRF7 when stimulated by dsRNA. 
Signalling is similar to the pathway previously described for TLR3. Activated MAD5 and 
RIG-I activate TBK1 and IKKε via the adaptor protein interferon-β promoter stimulator-
1 (ISP-1) (Kawai et al 2005, Meylan et al 2006). Protein kinase R (PKR) has been shown 
to activate NFκβ via activation of inhibitor of NFκB (IKK) which inactivates inhibitor of 
NFκB (IκB) (Kumar et al 1994, Zamanian-Daryoush et al 2000, Hovanessian 2007). 
 
1.2.3 The IFNα/β response 
IFNα/β is a group of cytokines integral to the anti-viral immune response capable 
of inducing an anti-viral state in an autocrine and paracrine manner signalling 
through IFNα/β receptor (Figure 1.6). As described above, all cell types can 
mount an IFNα/β response; however the exact mechanism of induction is diverse 
and dependent upon cell type and viral recognition receptors. IFNα/β anti-viral 
actions include activation of NK-cells and DCs, promotion of cross-presentation 
and production of IFNγ from DCs and T-cells, favouring a Th1-cell mediated 
immune response (Haeryfar 2005). 
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Figure1.6 Schematic picture of IFN signalling (adapted from Haller et al 2007). 
Signalling via the IFNα/β receptor (IFNR) employs the JAK/STAT pathway. This pathway 
includes Janus kinase (JAK1), tyrosine kinase 2 (TYK2) and signal transducer and 
activator of transcription (STAT1 and STAT2). Activation of the receptor leads to 
dimerisation of STAT1 and STAT2 and subsequent translocation to the nucleus where the 
heterodimer interacts with interferon regulatory factor 9 (IRF9). The complex formed is 
called interferon stimulated gene factor 3 (ISGF3) and binds to interferon stimulated 
response element (ISRE) in promoters of IFN stimulated genes (ISG). The result is 
upregulation of hundreds of genes responsible for creating an antiviral sate in the cell. 
The functions of a few of these genes have been investigated in detail. Important 
mediators of the cellular antiviral response are protein kinase R (PKR), 2’5’-
oligoadenylate synthetase (OAS) and the Mx protein. The result of IFNα/β stimulation 
includes shutting down cellular protein synthesis, arresting the cell cycle and establishing 
a pro-apoptotic state in the cell (Randall and Goodbourn 2008). In contrast to the 
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ubiquitously expressed IRF3, expression of IRF7 is normally very sparse (except in 
plasmacytoid dendritic cells also called natural interferon cells). IFNα/β upregulate IRF7 
expression which amplifies the interferon response in a positive feedback loop (Paun and 
Pitha 2007). 
 
1.3 Dendritic cells (DCs) 
DCs were first described in 1973 by Steinman and Cohnin. It is now clear that 
DCs compromise a very heterogeneous population of cells with different 
functions and specific expression patterns of cell surface markers. The bovine 
system does not seem to be an exception when it comes to heterogeneity in DC 
populations. At least two subsets of DCs that show functional differences in vitro 
have been differentiated in bovine afferent lymph (Howard et al 1997, Howard et 
al 1999, Stephens et al 2003). All DCs are however derived from a common 
multipotent haematopoietic stem cell and can be generated from either myeloid or 
lymphoid precursors (Shortman and Liu 2002, Fitzgerald-Bocarsly and Feng 
2007). A broad, commonly encountered division of DC populations is 
conventional DCs (cDCs) versus plasmacytoid DCs (pDCs). The latter of these 
two is at present under characterisation in the bovine system (unpublished data, A. 
Stalker personal communication). The major task of pDCs during viral infections 
is production of vast amounts IFNα/β and less so antigen presentation (Carbone et 
al 2003, Haeryfar 2005). The following general description of DC function 
applies to the cDC.  
1.3.1 Functions of immature DCs- antigen uptake 
In their immature state DCs act as sentinels of the immune system. Strategically 
scattered in close proximity with epithelium outlining body surfaces they 
constantly sample the environment for antigen. DCs are extremely efficient in 
antigen uptake by a number of different mechanisms such as constitutive 
macropinocytosis (Sallusto et al 1995) (this has not been demonstrated in bovine 
monocyte derived DCs (mDCs) (Werling et al 1999)), receptor mediated 
endocytosis (Sallusto and Lanzavecchia et al 1994, Arnold-Schild et al 1999), 
phagocytosis (Reis e Sousa et al 1993) and caveaolae formation (Werling et al 
1999). In addition to antigen uptake, innate properties of DCs include cytokine 
production and production of anti-microbial proteins and peptides such as 
defensins and members of the complement system. Production of interleukin-12 
(IL-12) and IFNα/β provides innate resistance, activating natural killer cells (NK-
cells) and IFNα/β, stimulating antiviral defenses. The mobilised NK-cells and the 
produced cytokines (e.g. IL-12 and IFNα/β) act back on the DCs to drive their 
maturation but also to influence the subsequent adaptive immune response 
(Andoniou et al 2005, Steinmann and Hemmi 2006). 
1.3.2 Functions of mature DCs- antigen presentation 
Recognition of PAMPs via PRRs along with stimulation by pro-inflammatory 
cytokines (such as TNFα and IL-1β) leads to activation and maturation of DCs. 
During maturation DCs change from being a specialised phagocyte in the 
periphery to becoming a professional antigen presenting cell (APC) able to 
activate antigen specific T-cell clones in secondary lymphoid tissues. En route, 
DCs acquire the characteristic dendritic shape, increase expression of surface co-
stimulatory molecules (such as CD40, CD80 and CD86), process and present 
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antigen on major histocompatibility complexes (MHC I and II) allowing efficient 
contact with, and activation of, naïve T-cells upon reaching the T-cell paracortex. 
Depending on the stimuli initiating DC maturation the DC will initiate different T-
cell responses, in that way shaping the adaptive response to suit the specific 
pathogen (Pulendran et al 2001). The nature of the adaptive response is 
determined firstly by the peptide-MHC complex presented (endogenous antigen 
on MHC I and exogenous antigen on MHC II presented to CD8
+
T-cells and 
CD4
+
T-cells respectively) and secondly by the cytokines present in the 
microenvironment, for instance production of IL-12 and IFNγ will result in a Th1-
biased cell mediated immune response (Mellman and Steinman 2001, Steinmann 
and Hemmi 2006). Furthermore, DCs seem to be the cell type with the most 
evolved cross-presenting abilities (Hotta et al 2005). Cross-presentation of 
antigen to CD8+T-cells is important when APCs are resistant to the infecting 
virus enabling extracellular antigen to be presented on MHC class I. This allows 
uninfected APCs to present antigen from engulfed virus infected cells on MHC 
class I stimulating CD8
+
T-cells (Brode and Macary 2004). 
1.3.3 Bovine mDCs 
The most common procedure for generating DCs is culturing the easiest 
accessible DC precursor; the blood monocyte with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and IL-4 (IL-4) (Romani et al 1994). This 
procedure has also been described for production of bovine mDCs (Werling et al 
1999). Bovine DCs derived from blood monocytes express moderate to high 
levels of costimulatory molecules and MHC class II molecules and have a down 
regulated expression of the myeloid cell differentiation molecule CD14, 
commonly used as a marker for monocytes (Beekhuizen et al 1991, Bajer et al 
2003,). Bovine mDCs provide a good tool for studying DC function in vitro.  
 
1.4 BVDV and immunity 
The interaction between BVDV and the host’s immune system is a key feature in 
the BVDV disease complex. Establishment of persistent infections in the foetus is 
the most evident outcome of the ability of BVDV to subvert the immune system. 
Another effect of BVDV on the immune system is transient immunosuppression 
associated with acute infections. The mechanism behind this effect is under 
investigation, for a good review see Chase et al 2004. BVDV has been shown to 
infect many immune cells including T-cells, B-cells, monocytes, macrophages and 
DCs (Sopp et al 1994, Glew et al 2003). Infecting APCs (macrophages, DCs and 
B-cells) has the potential to strongly affect the immune response since they have a 
key role in inducing and shaping the adaptive immune response.  
So far most research has focused on how BVDV affects bovine monocyte and 
macrophage function. BVDV has been shown to alter function of TLRs, 
expression of cytokines and costimulatory molecules in bovine monocytes and 
macrophages (Franchini et al 2006, Lee et al 2007) resulting in an adverse affect 
on their ability to stimulate Th-cells (Glew et al 2003). No impairment of APC-
function has however been demonstrated for BVDV infected DCs.  
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1.4.1 In Utero Infections and Generation of PIs 
Both BVDV biotypes interact differently with the immune system, with the most 
documented distinction being the capacity to stimulate IFNα/β production (Table 
1.3).  
 
Table 1.3 IFNα/β production in response to BVDV infection 
BVDV biotype Effect on type I interferon production 
 
Cytopathogenic IFNα/β↑in vitro and in vivo including the 
early foetus 
 
Non-cytopathogenic IFNα/β↓in vitro in most cell types and in 
vivo in the early foetus 
IFNα/β↑in vivo apart from in the early 
foetus 
 
Differential effects of BVDVcp and BVDVncp on IFNα/β production (adapted from Chase 
et al 2004). In vitro studies have shown that BVDVcp but not BVDVncp induces IFNα/β 
production (Adler et al 1997, Peterhans et al 2003, Glew et al 2003). It has also been 
demonstrated that BVDVcp induces IFNα/β production in the early foetus whereas 
BVDVncp does not (Charlston et al 2001) thus, the incapability of cp virus to establish 
persistent infections. Infection of immunocompetent calves with BVDVncp on the other 
hand results in production of IFNα/β (Charleston et al 2002, Müller-Doblies et al 2004). 
This difference in interferon response to BVDVncp infection in the foetus and the 
immunocompetent calf may be dependent on the developmental stage of the innate 
immune system. The cellular source of IFNα/β in BVDV infections could be the bovine 
equivalent to plasmacytoid dendritic cells which have not yet been fully characterized in 
cattle. Identification of this interferon producing cell explains why BVDVncp does not 
induce any detectable interferon response in other cell types in vitro in contrast to the 
interferon levels detected in vivo following infection with BVDVncp (Brackenbury et al 
2005).  
 
Unlike BVDVcp, BVDVncp evades the IFNα/β response in the early foetus 
enabling the establishment of persistent infection (PI). Both biotypes can cross the 
placenta to initiate foetal infection; however the outcome is dependent upon both 
the developmental stage of the foetus and the biotype (Table 1.4). 
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Table 1.4 Outcomes of in utero infections with BVDVncp 
Time of infection Consequence  
 
First trimester (0 to 110 days) 
 
Abortions, foetal mummification, 
congenital damage in organs with active 
cell division at the time of infection (lungs, 
skin, eyes, thymus and CNS are the organs 
most commonly affected) 
Establishment of persistent infections 
 
Second trimester (110 to 180/200 days) 
 
 
Foetal loss and congenital damage 
Third trimester (200 and onwards) 
 
The immune system is mature enough to 
mount a protective response  
 
Outcomes of in utero infections with BVDVncp (adapted from Brownlie et al 2000) 
 
Whereas BVDVcp infection seems to be cleared by the foetus, BVDVncp 
infection of a seronegative dam results in a high frequency of abortions, 
congenital damage and if infection occurs in the first trimester might result in the 
birth of a PI animal (Brownlie 1989, Brownlie 1991). At this stage, the immune 
system of the foetus is not yet developed and cannot clear the virus, resulting in 
tolerance to the infecting virus. PI animals are the main source of virus within a 
herd, constantly excreting large amounts of virus, creating an important 
transmission route during movement (Brownlie et al 1986, Houe 1999). A further 
complication with PI animals is the development of inevitably fatal Mucosal 
Disease (MD) associated with severe lesions within the mucosa of the 
gastrointestinal tract. Experimentally, MD can be induced in PIs from 
seronegative dams infected with BVDVncp in the first trimester and subsequently 
superinfected with antigenically homologous BVDVcp or through spontaneous 
conversion of BVDVncp to BVDVcp (Brownlie et al 1984, Bolin. et al 1985, 
Brownlie 1991, Brownlie and Clarke 1993). The exact pathogenesis behind 
lesions observed in MD and the mechanisms for conversion of BVDVncp to 
BVDVcp is largely unknown.  
1.4.2 Acute BVDV Infections  
Acute infections can be caused by both biotypes of BVDV where the outcome is 
highly variable mostly due to virulence of the individual strain (Table 1.5). 
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Table 1.5 Outcomes of acute transient BVDV infections 
 
Virulence Clinical signs and findings Viral spread 
 
Low virulence 
 
No evident clinical signs 
Mild pyrexia, mild 
leucopenia and decreased 
milk production 
 
Virus mainly confined to 
lymphoid organs but also 
detected in the intestinal 
mucosa 
High virulence 
 
 
Severe pyrexia, anorexia, 
depression, diarrhoea, 
occulo-nasal discharge, 
respiratory distress, 
haemorrhage, severe 
lymphopenia and 
thrombocytopenia, high 
mortality in all age groups 
Lesions include cell 
depletion in lymphoid 
organs, epithelial necrosis 
in the GI tract and 
pneumonia 
Predominantly in lymphoid 
tissues, mucosa of the GI 
tract, respiratory tract, 
endocrine organs, bone 
marrow but eventually 
general spread to most 
organs 
 
Overview of the most frequently seen outcomes of acute BVDV infections caused by 
strains of high and low virulence. (Development of clinical signs and distribution of the 
virus have been documented in field cases and experimental infections Pritchard et al 
1989, Sol et al 1989, Wilhelmsen et al 1990, Hibberd et al 1993, David et al 1994, Marshall 
et al 1996, Spagnuolo-Weaver et al 1997, Bruschke et al 1998, Carman et al 1998, Odeón 
et al 1999, Hamers et al 2000, Stoffregen et al 2000, Muskens et al 2004, Dabak et al 
2007) Hypervirulent strains predominantly belong to the BVDV2 genotype and are 
largely confined to North America (Pellerin et al 1994). However all BVDV2 strains are 
not hypervirulent (Ridpath et al 2000) and outbreaks of severe acute BVDV infections 
have also been caused by strains identified as BVDV1 (Hibbered et al 1993, Muskens et 
al 2004 and Hamers et al 2000) Both low and high virulent strains initially replicates in 
the nasal mucosa (Bruschke et al 1998) followed by spread of the virus to various tissues. 
Strains of high virulence show a more widespread distribution than low virulent strains. 
Severe clinical signs are correlated with a higher level of viremia (Walz 2001) but 
specific virulence factors for BVDV have not yet been characterized. The pathogenesis 
behind the lymphocyte depletion, thrombocytopenia and mucosal lesions is unknown.  
 
Most acute infections are mild or subclinical; however the incidence of severe 
acute BVDV infections is increasing (Pritchard et al 1989, Sol et al 1989, 
Hibberd et al 1993, David et al 1994, Carman et al 1998, Muskens et al 2004). 
Mild infections should not be neglected, BVDV infections are suspected to cause 
immunosuppressive effects (Brownlie 1991) and if concurrent with insemination, 
result in reduced conception and pregnancy rates in heifers (McGowan et al 
1993). Acute infections are cleared however, with protective antibodies generally 
being detected 2-3 weeks post infection for which CD4+T-cells are required 
(Howard et al 1992). Adaptive immune responses to BVDV also differs between 
biotypes, with BVDVncp inducing a stronger, faster humoral Th2-biased response 
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than BVDVcp which mostly results in a Th1-biased, cell mediated immune 
response (Lambot et al 1997, Rhodes et al 1999, Collen et al 2000). 
 
1.5 Aims and hypothesis of the project 
Until recently most research has focused on the differences between BVDVncp 
and BVDVcp, however the increase in incidence of severe type 1 BVDVncp 
infections asks for more knowledge about BVDVncp strain virulence. Knowledge 
about how ncp strains of different virulence interact with the immune system may 
explain how BVDVncp infections can result in such an array of diverse 
syndromes as persistent infection, subclinical transient infections and fatal 
disease.  
The aim of this project is to compare cytokine production from bovine mDCs 
stimulated with the BVDVncp type 1 strains, Ho916ncp and Ky1203ncp. 
Ho916ncp was originally isolated from a severe fatal outbreak of BVDV in a 
dairy herd 1993 (Hibberd et al 1993). Experimental infection of gnotobiotic 
calves with Ho916ncp resulted in prolonged viremia (more than 2 weeks, to be 
compared with 7-10 days for mild transient infections) and marked 
thrombocytopenia which is rare for type 1 isolates (unpublished data, J. Brownlie, 
personal communication). In contrast to Ho916ncp which can be described as 
causing acute severe disease, Ky1203ncp (originally isolated from a field case of 
MD) is associated with mild acute disease (J. Brownlie personal communication).  
The hypothesis is that these two ncpBVDV type 1 strains associated with different 
clinical outcomes also will differ in the cytokine response they induce from 
mDCs.  
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MATERIAL AND METHODS 
 
2.1 Experimental outline  
Peripheral blood mononuclear cells (PBMCs) were isolated from 3 animals. 
CD14+ cells were enriched by magnetic cell sorting (MACS) and cultured in the 
presence of recombinant bovine (rbo) IL-4 and rboGM-CSF for 6 days to 
differentiate into mDCs (Figure 2.1). mDCs were infected with virus strains 
Ho916ncp and Ky1203ncp, respective mock and control ligands. After 48 hrs 
cells were harvested, isolating supernatants and cell lysates. To analyse 
supernatants for IFNα/β production a chloramphenicol acetyltransferase (CAT) 
enzyme reporter gene assay was employed. Protein and RNA were extracted from 
cell lysates and cDNA synthesised to asses expression levels of IL-10 and IL-12 
by quantitative polymerase chain reaction (qPCR). Protein extracts were analysed 
by Western blotting for IRF3 and 7. In addition, the ability of the BVDV strains to 
infect mDCs was examined by immunoperoxidase (IPX) staining. Unstimulated 
mDCs and transfected Mardin-Darby bovine kidney cells (MDBKt2) cells were 
screened for BVDV and TLR-expression by reverse transcriptase PCR. 
Expression of CD14 was assessed by flow cytometry on isolated CD14+ cells and 
compared with the same cells after 6 days culturing with rboIL-4 and rboGM-
CSF. All cell culturing and virus work was carried out in class II safety hoods.  
Figure 2.1 Experimental outline and timeline showing the hypothetical minimal time 
required for processing and analyzing one set of samples. Due to a number of practical 
issues like limited access to lab facilities and restricted time points for bleeding animals 
this hypothetical timeline could not be followed. After day 8, harvesting of the stimulated 
mDCs cell lysates and supernatants were stored at -20° until following processing of 
samples could be performed. mDCs were isolated from 3 animals and stimulated with 
virus but due to the time limit only the interferon assay was carried out for all 3. Western 
blot and qPCR analysis were only completed for 2 animals.  
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2.2 Animals and blood collection 
Blood was collected from 3 Holstein-Friesian bullocks between 6 and 8 months of 
age housed at Bolton Farm at the Royal Veterinary College, UK. All animals were 
tested for BVDV antibodies and presence of viral nucleic acid by the Veterinary 
Laboratories Agency, UK. Blood was collected from the jugular vein into sterile 
glass bottles using 10% acid citrate dextrose (ACD) buffer as anticoagulant 
(Appendix 1).  
 
2.3 mDCs 
2.3.1 Isolation of monocytes and generation of mDCs 
PBMCs were isolated from whole blood as previously described (Werling et al 
1999) with minor modifications. Blood was added to 50ml Falcon tubes and buffy 
coat isolated by centrifugation (1500 g, 20 min). The buffy coat was washed with 
phosphate buffered saline (PBS) (Sigma Aldrich, UK) (300 g for 10 min at 4
°
C). 
Red blood cells were lysed by incubation in ammonium-chloride lysis buffer for 
10 min (Appendix 1) and white blood cells washed three times with PBS (600 g 
for 10 min at 4
°
C). The cell pellet was resuspended in 30 ml PBS and under-laid 
with 15 ml Histopaque (density=1.083 g ml
-1
, Sigma Aldrich, UK). After 45 min 
centrifugation at 1200 g at room temperature (RT) PBMCs were isolated from the 
interface layer. After two more washes in PBS the PBMCs were counted and their 
viability assessed by Tryphan Blue exclusion (0.1% Sigma Aldrich).  
To isolate monocytes, PBMCs were incubated with mouse anti human CD14 
coated paramagnetic microbeads and separated using a MidiMacs column 
(Miltenyi Biotech, Germany) according to manufacturer’s instructions. To 
generate DCs, CD14
+
 enriched cells were cultured at 2 x 10
6
 cells per well in 6 
well low-binding plates (Corning, Sigma Aldrich, UK) using mDC media 
(Appendix 1) containing rboIL-4 and rboGM-CSF (Glew et al 2003, Werling et al 
2006). Cells were cultured for 6 days, and every second day 2 ml media was 
replaced. On day 6, media was removed and mDCs harvested using 1 ml Accutase 
(PAA, Austria) per well to dislodge cells from the plastic.  
2.3.2 Flow cytometric analysis of CD14 expression on monocytes and 
mDCs 
Monocytes and mDCs were adjusted to a concentration of 8 x 10
6
cells ml
-1
 in PBS 
1%BSA 0.01%NaN3 (Appendix 1). 25 μl of the cell suspension was added to 
labeled wells on a 96 well U-bottom plate (Greiner, Germany). After 2 min 
centrifugation 170 g for 2 min at 4
°
C, discarding supernatant the cells were 
resuspended in 25 μl sterile filtered goat serum (Sigma-Aldrich, UK) and 
incubated 10 min at RT. Cells were stained with 25 μl FITC-conjugated mouse 
antihuman CD14 TÜK4 clone antibody (Ab) (Serotec, UK) diluted 1:10 in PBS 
1%BSA 0.01%NaN3. 25 μl PBS 1%BSA 0.01%NaN3 was added to negative 
control wells. After 15 min incubation in darkness cells were centrifuged as above 
before resuspended in 400 μl PBS and analysed by a BD FACSAria Flow 
Cytometer (Immunocytometry Systems, BD Biosciences, UK). Generated data 
was further analyzed in FlowJo (Version 7.2.1 TreeStar, USA).  
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2.4 Susceptibility of mDCs to BVDV infection 
2.4.1 Infection of mDCs with BVDV 
mDCs cultured in 24 well plates (Greiner, Germany) at 1 x 10
5
 cells per well in 
mDC media were infected with the BVDV strains Ho916ncp and Ky1203ncp at a 
multiplicity of infection (MOI) of 0.1. The virus stocks were kindly supplied by J. 
Brownlie, RVC, UK, grown and titred as described (Brownlie et al 1984) with a 
determined titre of 3.65 x 10
5
 TCID50 ml
-1
 and 1.12 x 10
6 
TCID50 ml
-1
 
respectively. BVDV strain NADL was used as a positive control to generate 
distinctive IPX staining results. The NADL BVDV strain as well as MDBK-cells 
were included as positive controls for staining procedures and infectivity assays, 
respectively (Deregt D. and Prins S. 1998). MDBK-cells were cultured to 80% 
confluency in MDBK growth media (Appendix 1) at 37˚C, 5% CO2 and in MDBK 
assay media (Appendix 1) at 1 x 10
5
 per well for the infection assay. Infected cells 
(summarized in Table 2.1) were incubated 24 hrs at 37˚C, 5% CO2. 
 
Table 2.1 Conditions used to study susceptibility of mDCs to Ho916ncp and Ky1203ncp 
 
Cell type Virus 
mDC - 
mDC NADL 
mDC Ho916ncp 
MDBK Ho916ncp 
mDC Ky1203ncp 
MDBK Ky1203ncp 
Each condition was set up in duplicate. The virus strains were separated on different 
plates to minimize the contamination risk. This experiment was set up in 3 individual 
repeats with mDCs isolated from different animals.  
 
2.4.2 IPX staining 
IPX staining was used to identify BVDV infected cells by light microscopy (Ward 
and Kaeberle 1984). Cells were fixed in 80% ice cold acetone (BDH, VWR, UK) 
for 30 min at -20˚C. IPX staining was performed incubating cells with 
hyperimmune BVDV serum (V182, J. Brownlie), diluted 1:100 in PBS-Tween 
(PBS-T) 5% normal rabbit serum (NRS) (Appendix 1) for 20 min at 37˚C, 
followed by four times washing in PBS-T. Thereafter, cells were incubated with 
anti-bovine horseradish peroxidase conjungate Ab (Sigma Aldrich, UK; diluted 
1:2000 in PBS-T 5% NRS) as described above. Cells were washed as described, 
and Ab binding was visualised by incubation with di-amino benzidine (DAB) 
substrate (Sigma Aldrich, UK) in darkness for 20-30 min. Cells were examined 
using an inverted microscope. Brown, cytoplasmic staining indicated presence of 
BVDV.  
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2.5 Stimulation of IFNα/β production in mDCs 
mDCs were plated at 5 x 10
5 
cells per well in flat bottom 96well plate (Greiner, 
Germany) in mDC media (Appendix 1). Plates were incubated at 37˚C, 5% CO2 
to let cells adhere before stimulated with ligands, 4 wells per ligand (Table 2.2, 
Figure 2.2). 
Table 2.2 Stimulation ligands 
Ligands used to stimulate mDCs. * Denotes phosphorothioate bond. Poly(I:C) from 
Alexis Biochemical, UK and CpG  from Coley Pharmacueticals, USA. CpG 2243 is a 
scrambled control sequence.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Plate layout for stimulation of mDCs. Plates were harvested after 48 hrs 
incubation at 37˚C, 5% CO2. Supernatants were collected from the first two wells of each 
condition (green) and RNA extracted from the cells. From the second two wells (red) the 
supernatant was discarded and protein extracted.  
 
The total volume in each well was adjusted to 200 μl with mDC media and plates 
incubated 48 hrs at 37˚C, 5% CO2. Supernatant from 2 wells of each condition 
was collected for IFNα/β analysis. Cells were washed once with PBS and 
thereafter prepared for RNA extraction or protein extraction using RLT buffer 
Ligand Sequence/Details  Concentration  
Poly(I:C) polyinosinic: polycytidylic acid  10 μg ml-1 
CpG 2336 G*G*GGACGACGTCGTGG*G*G*G*G*G 50  μg ml-1 
CpG 2243 G*G*G*GGAGCATGCTGG*G*G*G*G*G 50  μg ml-1 
BVDV 
Ho916ncp 
Ho916ncp infected MDBK cell lysate supernatants MOI of 0.1 
Mock Ho916ncp  Mock infected MDBK cell lysate supernatants MOI of 0.1  
BVDV 
Ky1203ncp 
Ky1203ncp infected MDBK cell lysate supernatants MOI of 0.1 
Mock 
Ky1203ncp  
Mock infected MDBK cell lysate supernatants MOI of 0.1 
 
 
 
 
 
 
 
 
Ky1203ncpMOC
K 
Ho916ncp, MOI 
0.1 
Ky1203ncp, MOI 
0.1 
Ho916ncpMOCK 
mDC media 
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CpG 2243 
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(QIAGEN, UK) or Mammalian Protein Extraction Reagent (MPER) mixed with 
Halt protease inhibitor (Thermo Scientific, UK) according to manufacturers’ 
protocol. Samples were stored at -20˚C.  
 
2.6 Detection of IFNα/β 
2.6.1 Sub-culturing MDBKt2-cells 
MDBKt2-cells were cultured until 80% confluent at 37˚C, 5% CO2 in MDBKt2 
media (Appendix 1). MDBKt2-cells were used for IFNα/β detection in 
supernatants from stimulated mDCs using a CAT enzyme reporter gene assay as 
previously described (Fray et al 2001). The MDBKt2-cells are transfected with a 
plasmid containing the human Mx gene promoter coupled with a gene encoding 
CAT-enzyme. IFNα/β stimulate the Mx promoter inducing transcription of CAT 
enzyme. The amount of CAT-enzyme can be quantified by a commercially 
available enzyme linked immunosorbant assay-kit (CAT-ELISA; Roche 
Diagnostics, Germany). 
For the CAT reporter gene assay MDBKt2-cells were plated in 24 well plates 
(Greiner, Germany) at 2.5 x 10
5
cells per well in 2% MDBKt2 assay media 
(Appendix 1). After 24 hrs in culture, media was removed and cells washed with 
PBS before adding 400 μl MDBKt2 2% assay per well. 100 μl of either mDC-
supernatant, recombinant human (rhu)IFNα (NIBSC, UK), or rboIFNα (Molecular 
Immunology, RVC) was used to create a standard curve as well as internal 
reference. To do so, 250 international units (IU) of rhuIFN were serial diluted 1:2, 
whereas rboIFN was serial diluted 1:4. Plates were incubated 24 hrs at 37˚C, 5% 
CO2 and thereafter stored at -20˚.  
2.6.2 Stimulation of MDBKt2-cells 
To assess the ability of MDBKt2-cells to directly respond to IFNα/β-inducing 
ligands or BVDV virus, MDBKt2-cells were stimulated as described in 2.5 and 
cell lysates analysed by the CAT-ELISA kit.  
2.6.3 CAT-ELISA 
The CAT-ELISA was performed as according manufacturer’s protocol, and the 
principle of this sandwich ELISA is shown in Figure 2.3. and Figure 2.4.  
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Figure 2.3 Principle for sandwich ELISA detecting CAT-enzyme. The ELISA plate is 
coated with anti-CAT antibodies. The secondary anti-CAT antibody is labelled with 
digoxigenin. A F(ab)-fragment against digoxigenin conjugated with peroxidase will 
visualize antibody binding when peroxidase substrate is added. The reaction between 
substrate and peroxidase yields a coloured product.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substrate 
Anti-DIG-POD F(ab)-
fragment 
Anti-CAT-DIG 
CAT 
Anti-CAT-coated microplate 
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Figure 2.4 Schematic Flow Chart of CAT-ELISA protocol. 200 μl per well of samples and 
standards diluted 1:2 was added to the ELISA plate. After 1 hr incubation at 37˚C and x5 
washing with washing buffer 200 μl digoxigenin labelled anti-CAT antibody (anti-CAT-
DIG) was added per well. Incubation and washing was repeated before adding 200 μl 
peroxidase labelled anti-digoxigenin antibody (anti-DIG-POD) per well. After a final 
incubation and x5 wash 200 μl peroxidase substrate was added. The optical density (OD) 
of individual wells was read at 405 nm with 490 nm reference (SpectraMax M2 
microplate reader, Moleculer Devices, USA).  
 
2.7 RNA extraction 
Total RNA from mDC stimulated as described in section 2.5 was extracted using 
the RNeasy mini kit (QIAGEN, UK) according to manufacturer’s protocol. 
Extracted RNA was treated with RNase-free DNase I (Ambion (Europe) Ltd., 
UK) at 37°C for 20 min to remove contaminating genomic DNA. RNA yields and 
quality were determined using a NanoDrop
®
 ND-1000 Spectrophotometer 
(NanoDrop Technologies, USA) (260/280 ratio >1.9 regarded satisfactory).  
 
2.8 cDNA synthesis 
For each sample, 10 ng of RNA was transcribed to cDNA using the Supercript II 
reverse transcription system (Invitrogen, UK). Briefly, reverse transcription was 
performed using 200 units SuperScript II reverse transcriptase (Invitrogen, UK), 
500 ng oligo dT, 10 mM deoxyribonucleoside triphosphate (dNTPs) mix, 10 mM 
dithiothreitol (DTT), 5× first-strand buffer and 40 units RNAsin (Promega, UK). 
The reverse transcription reaction was allowed to proceed at 42°C for 50 min, 
followed by 70°C for 15 min. Synthesised cDNA was incubated at 37°C for 20 
min with 2 units RNase H (Promega) to remove original RNA templates. cDNA 
yields and quality were determined using a NanoDrop
®
 ND-1000 
Spectrophotometer. The integrity of the cDNA was assessed by PCR for the 
200 μl of standards 
and samples/well 
samples/well 
200 μl anti-CAT-DIG 
 
200 μl anti-DIG-POD 
 
POD substrate 
Analyse OD at 405 nm 
with 490nm reference 
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constitutively expressed gene β-actin (see 2.9 and Table 2.3). cDNA was stored at 
-20°C until required.  
To detect BVDV nucleic acid in potentially infected cells reverse transcription 
was performed as above but using 500 ng random hexamer primers (GE 
Healthcare, UK) instead of oligo dT primers. 
 
2.9 PCR 
PCR amplification of cDNA adjusted to 50ng µl
-1
 was carried out using primers 
listed in Table 2.3. A 50 µl reaction was used containing 50 ng cDNA template, 
10 pmol µl
-1
 sense and antisense primers, 10 mM dNTPs 10 mM, (Bioline, UK), 
1x GoTaq green reaction buffer (Promega, UK) and 1.25 units GoTaq DNA 
Polymerase (Promega, UK). Molecular Biology Water (Sigma Aldrich, UK) was 
used as negative control and plasmid preps (0.5 µl per reaction) as positive 
controls (Appendix 2). The reaction was heated to 94°C for 2 min, followed by 30 
cycles of 94°C for 40 sec, 55°C for 1 min, 72 °C for 1 min, and a final extension 
step of 72°C for 7 min. PCR was performed on a G-STORM thermocycler (GRI 
systems, UK). 
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Table 2.3 PCR primers  
 
PCR products were analysed by electrophoresis (100 V, 30 min) on a 1% agarose 
gel containing 1 µl Safe View (NBS Biologicals, UK) loading 5 µl of each PCR 
product and 5 µl 100 bp DNA Ladder (Fermentas, Germany). DNA bands were 
visualised by ultraviolet transillumination. 
 
2.10 TaqMan® qPCR  
mRNA expression of IL-10 and IL-12 from mDCs stimulated as described in 
(Section 2.5) was quantified using TaqMan® qPCR techonolgy. Primers and 
TaqMan® probes were previously designed at Institute of Animal Health (IAH), 
Compton, UK using primer Express software (Applied Biosystems, Foster City, 
CA, USA) (Table 2.4). Primers and probes were used at a concentration of 3x10
-7
 
M and 1x10
-7 
M respectively. Probes were labelled at the 5’ end with the reporter 
dye FAM (6-carboxyfluorescein) and at the 3’ end with the quencher dye 
TAMARA (6-carboxytetramethyl-rhodamine). qPCR was carried out using Taq 
Man® Universal PCR Mastermix (Applied Biosystems), with 100 ng cDNA as a 
template, on ABI 7500 Fast sequence detection system (Applied Biosystems). The 
amplification cycle consisted of an initial denaturation step of 95°C for 10 min, 
followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. Results were 
quantified by comparison with standard curves of known copy numbers of 
Gene (Accession 
Number) 
Forward Primer Reverse Primer Expected 
size 
Bovine β-actin 
(AY141970) 
CCA GAC AGC ACT 
GTG TTG GC 
GAG GAA GCT GTG 
CTA CGT CGC 
300 bp 
Bovine TLR1 
(AY634638) 
TTC CAG AGC TGC 
CAG AAG AT 
GAG ATT GTG GTG 
GGC AAA GT 
627 bp 
Bovine TLR2 
(AY634629) 
CAG CAA CTG AAG 
ACG TTG GA 
CAC CAC TCG CTC 
TTC ACA AA 
571 bp 
Bovine TLR3 
(AY812026) 
CCC CAG TCT CAC 
AGA GAA GC 
CCT GTG AGT TCT 
TGC CCA AT 
645 bp 
Bovine TLR4 
(AY634630) 
TGC TGG CTG CAA 
AAA GTA TG 
TCT GCA GGA CGA 
TGA AGA TG 
335 bp 
Bovine TLR5 
(AY634631) 
TGC ATC CAG ATG 
CTT TTC AG 
CCT TCA GCT CCT 
GGA GTG TC 
618 bp 
Bovine TLR6 
(AY487803) 
AGG CCA AGT ATC 
CAG TGA CG 
GAG ATT GTG GTG 
GGC AAA GT 
538 bp 
Bovine TLR7 
(AY487802) 
GGA AAT TGC CCT 
CGT TGT TA 
TGC AGT GTT TCA 
AGG ACC TG 
620 bp 
Bovine TLR8 
(AY642125) 
TTG ATG ACG ATG 
CTG CTT TC 
GGG TTA CCC CCT 
AGT TCC AA 
665 bp 
Bovine TLR9 
(AY859726) 
CAA GTG CTC GAC 
CTG AGT GA 
CCA TGG TAC AGG 
TCC AGC TT 
690 bp 
Bovine TLR10 
(AY634632) 
CAC CTG ACA TCT 
TTG CGA GA 
TTC CCT CAT GAA 
GGC AAA TC 
602 bp 
BVDV 5’ UTR 
(M31182) 
ATG CCC ATA GTA 
GGA CTA GCA 
TCA ACT CCA TGT 
GCC ATG TAC 
287 bp 
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plasmid DNA containing targeted gene sequences. To ensure that each sample 
contained cDNA of the same amount and quality (testing efficacy of RNA 
extraction and cDNA synthesis), expression of the housekeeping genes 
glyceraldehyde-3-phosphate dehydrogenase (GADPH) and the ribosomal protein 
RPLPO was measured in each sample. Samples, standards and no template 
controls were set up in triplicate. Data analysis was carried out using Microsoft® 
Excel 2007 (Microsoft Co, USA).  
 
Table 2.4 Primers and probes for Taq Man® qPCR 
Target Forward primer Reverse primer Probe 
GADPH CAT GTT CCA GTA 
TGA TTC CAC CC 
GAG CTT CCC GTT 
CTC TGC C 
CGG CAA GTT CAA 
CGG CAC AGT CA 
RPLPO GCA CAA TTG AAA 
TCC TGA GTG 
GGG TTG TAG ATG 
CTG CCA TT 
AGC GAA GCC ACG 
CTG CTG AA 
IL-10 GGT GAT GCC ACA 
GGC TGA G 
AGC TTC TCC CCC 
AGT GAG TTC 
CAC GGG CCT GAC 
ATC AAG GAG CA 
IL-
12p40 
CCA AAG TCA CAT 
GCC ACA AGG 
CTG TAG TAG CGG 
TCC CGG G 
TGC CAA CGT CCG 
CGT GCA A 
 
2.11 Western blotting (WB) 
Protein concentrations were determined using a NanoDrop
®
 ND-1000 
Spectrophotometer. Samples were prepared for reducing sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) by adding 5x Laemmli buffer 
(Appendix 1) and 8 min boiling. After brief re-heating, 10 µl sample per well (5 
µg protein) was loaded to a 10% Tris-HCl gel (Bio-Rad, UK), ran at 30 mA per 
gel for 90 min. The proteins separated by size were transferred to 0.2 µm 
nitrocellulose membranes (Amersham Biosciences, Germany). PBS-T/5% non-fat 
milk powder (Appendix 1) was used for blocking membranes (1 hr at RT with 
gentle agitation), diluting Ab and washing off unbound Ab. Membranes were 
incubated with Abs listed in Table 2.5. ß-actin was used as a protein loading 
control on membranes treated with stripping buffer (Thermo Sceintific, UK) 
according to manufacturer’s prtocol. Ab binding was visualised using the ECL 
system (Amersham Biosciences, Germany) according to manufacturer’s protocol 
and a Curix 60 processor (Agfa-Gevaert N.V., Mortsel-Belgium).  
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Table 2.5 WB Antibodies and Conditions 
Antibody 
Concentration 
and incubation 
Specificity Molecular Weight 
IRF3  1:200, over night 
Polyclonal rabbit anti-Human IRF3 (FL-
425)* 
~50 kDa 
IRF7 1:200, over night 
Polyclonal rabbit anti-Human IRF7 (H-
246)* 
~50 kDa 
β-actin 1:5000, 1 hr Monoclonal mouse anti-Actin Clone C4** ~42 kDa 
* Santa Cruz Biotechnologies Inc, USA)  ** Millipore (Chemicon), UK. See Appendix 4 
for further details.  
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RESULTS 
 
3.1 Generation of mDCs 
3.1.1 Morphology 
mDCs were generated by culturing CD14
+
 cells for 6 days with rboIL-4 and 
rboGM-CSF. By day 6 cells were adhering to the plastic and an irregularly large 
cytoplasm with projections could be observed by light microscopy (Figure 3.1). 
 
 
 
 
Day 0 
Day 1 
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Day 3 
Day 2 
Day 4 
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Figure 3.1 Differentiation of monocytes to mDCs. Representative pictures showing 
culturing of CD14
+
 cells for 6 days in culture media supplemented with IL-4 and GM-
CSF. Magnification 100x (Olympus CK2 inverted microscope). Arrows indicate 
cytoplasmic protrusions, a characteristic feature of DC morphology. 
 
Forward/Side Scatter analysis by flow cytometry of enriched CD14
+
 cells before 
and after 6 days culturing with rboIL-4 and rboGM-CSF also illustrates a change 
in morphology (Figure 3.2). Disregarding cellular debris and big granular dying 
cells sticking together, the Forward/Side scatter analysis of cultured cells show a 
fairly dense, homogenous cell population with a slight increase in size. 
 
Day 6 
Day 5 
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A  
 
B  
Figure 3.2 Dot plot showing CD14
+
 cells before and after 6 days culturing with rboIL-4 
and rboGM-CSF analysed for size (Forward Scatter FSC-A) and granularity (Side 
Scatter- SSC-A) by flow cytometry. 5000 cells were recorded using a FACSAria and data 
analysed in FlowJo (TreeStar, California, USA). A) CD14
+
 cells enriched by MACS, B) 
The same cells after 6 days in culture with IL-4 and GM-CSF. 
 
 
 
Freshly enriched 
CD14
+
 cells 
CD14
+
 after 6 
days in culture 
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3.1.2 CD14 expression 
After 6 days culturing of CD14
+
 enriched cells with rboIL-4 and rboGM-CSF 
FACS analysis showed a down regulation of CD14 expression (Figure 3.3). The 
staining picture varied between individual animals (3 individual repeats) but all 
showed the same trend of CD14 down regulation. 
 
 
Figure 3.3 FITC labeled CD14 antibody staining of monocytes (Mo) enriched by CD14
+
 
MACS before and after 6 days culturing with rboIL-4 and rboGM-CSF. Representative 
data from flow cytometric analysis of 5000 cells (A and B) and 30 000 cells (C and D) 
are presented as histograms. Data presented are based on uniformly gated cell 
populations as shown in Figure 3.2. A) monocytes, unstained B) monocytes, FITC CD14 
staining, C) mDCs, unstained D) FITC CD14 staining, mDCs 
 
Taken together, the changes in morphology and decreased CD14 expression 
demonstrate that isolated monocytes resemble mDCs after 6 days in culture.   
 
3.2 Reverse transcriptase PCR for TLR expression and presence of 
BVDV 
3.2.1 BVDV 
To ensure that cells were free from BVDV infection prior to stimulation with 
Ho961ncp and Ky1203ncp, cells were screened by reverse transcriptase PCR. 
mDCs isolated from the 3 animals used for the stimulation assay and MDBKt2-
cells used for the CAT-enzyme reporter gene assay all screened negative (Figure 
3.4).  
 
Mo, neg 
 
 Mo, stained 
stained 
mDCs, neg 
neg 
mDCs, stained 
A 
 
B 
 
C 
 
D 
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Figure 3.4 Screening for presence of BVDV nucleic acid in mDCs and MDBKt2 cells by 
reverse transcriptase PCR using primers described in Table 2.3. PCR products were 
analysed by gel electrophoresis on a 1% agarose gel containing 1 μl Safe View (NBS 
Biologicals, UK) and visualized by ultraviolet transillumination. A plasmid control 
cointaining 5’UTR sequence from the BVDV strain NADL (Appendix 2) was loaded next 
to a 100 bp ladder (Fermentas, Germany).  
 
3.2.2 mRNA expression of TLR3, 7, 8, 9 in mDCs and MDBKt2-cells 
To investigate the ability of mDCs to sense viral infection through TLR 
recognition, mRNA expression of TLR3, 7, 8 and 9 in unstimulated mDCs from 3 
animals was determined by reverse transcriptase PCR. This was also performed 
for MDBKt2-cells to explore their capability of TLR-dependent IFNα/β 
production. 
 
 
Figure 3.5 Representative result of reverse transcriptase PCR for mRNA expression of 
viral TLRs in mDCs and MDBKt2 -cells using primers described in Table 2.3. Each TLR 
set include a positive plasmid control containing bovine TLR constructs (Appendix 2) 
loaded next to a negative control
 
MDBKt2-cells were shown to express TLR3 and TLR9 (Figure 3.5 lane 4 and 
17). TLR expression in mDCs was largely consistent between the 3 animals 
(Table 3.1). PCR products of the right sizes (Table 2.3) were generated using 
1    2    3    4    5    6    7 
 1    2    3    4   5   6    7   8    9         10 11 12 13 14 15 16 17 18 
500 bp 
500 bp 
500 
bp 
1) ladder 
2) plasmid containing 5’UTR sequence from BVDV type 1 strain NADL 
3) negative control 
4) cDNA from MDBKt2 cells 
5) cDNA from mDCs animal 1 
6) cDNA from mDCs animal 2 
7) cDNA from mDCs animal 3 
 
1) Ladder 
2) plasmid containing bovine TLR3 
3) negative control TLR3  
4) cDNA from MDBKt2 cells, TLR3  
5) cDNA from mDCs animal 2, TLR3 
6) plasmid containing bovine TLR7 
7) negative control TLR7 
8) cDNA from MDBKt2 cells, TLR7  
9) cDNA from mDCs animal 2, TLR7 
 
 
10) Ladder 
11) Plasmid containing TLR8 
12) Negative control TLR8 
13) cDNA from MDBKt2 cells, TLR8  
14) cDNA from mDCs animal 2, TLR8 
15) plasmid containing bovine TLR9  
16) negative control TLR9  
17) cDNA from MDBKt2 cells, TLR9  
18) cDNA from mDCs animal 2, TLR9 
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primers for TLR3, 7 and 8 (Figure 3.5 lane 5, 9 and 14). TLR9 primers gave rise 
to a faint band only in mDCs from animal 2 (Figure 3.5 lane 18).  
3.2.3 mRNA expression of TLR1, 2, 4, 5, 6, 10 in mDCs  
mRNA expression of TLR1, 2, 4, 5, 6, and 10 in mDCs from 3 animals was 
investigated as a part of general characterisation.  
 
A  
 
 
 
 
 
 
 
B 
 
 
Figure 3.6 Representative result of reverse transcriptase PCR for mRNA expression of 
TLR1, 2, 4, 5 (A) and TLR6 and 10 (B) in mDCs cells using primers described in Table 
2.3. Each TLR set include a positive plasmid control containing bovine TLR constructs 
(Appendix 2) loaded next to a negative control.  
   1   2   3   4    5   6   7   8   9        10 11 12  13 14  15  16 17 18 
 1    2    3    4    5    6    7    8    9                        
500 bp 
bp 
10) ladder 
11) plasmid containing bovine TLR1  
12) negative control TLR1  
13) cDNA from mDCs animal 2, TLR1 
14) cDNA from mDCs animal 3, TLR1 
15) plasmid containing bovine TLR2  
16) negative control TLR2  
17) cDNA from mDCs animal 2, TLR2  
18) cDNA from mDCs animal 3, TLR2 
 
1) ladder 
2) plasmid containing bovine TLR1  
3) negative control TLR1  
4) cDNA from mDCs animal 2, TLR1 
5) cDNA from mDCs animal 3, TLR1 
6) plasmid containing bovine TLR2  
7) negative control TLR2  
8) cDNA from mDCs animal 2, TLR2  
9) cDNA from mDCs animal 3, TLR2 
 
1) ladder 
2) plasmid containingl bovineTLR6  
3) negative control TLR6  
4) cDNA from mDCs animal 2, TLR6 
5) cDNA from mDCs animal 3, TLR6 
6) plasmid containing bovine TLR10  
7) negative control TLR10 
8) cDNA from mDCs animal 2, TLR10  
9) cDNA from mDCs animal 3, TLR10 
Expression of TLR1, 2, 4, 5, 6 and 10 was largely consistent between the 3 
animals (Figure 3.6 A and B) only diverging in expression of TLR 10 for which 1 
out of 3 was positive. For an overview of TLR expression see Table 3.1.  
 
Table 3.1 Overview of reverse transcriptase PCR results for TLR expression in mDCs 
from 3 animals.  
TLR Presence in mDC 
TLR1 + 
TLR2 + 
TLR3 + 
TLR4 + 
TLR5 - 
TLR6 + 
TLR7 + 
TLR8 + 
TLR9 -/+ 
TLR10 -/+ 
  
3.3 Susceptibility of mDCs to BVDV infection 
3.3.1 IPX staining  
To investigate if isolated mDCs were susceptible to infection with either 
Ho916ncp or Ky1203ncp, mDCs were infected at a MOI of 0.1 and stained by 
IPX (48 hrs p.i. using BVDV hyperimmune serum). Brown cytoplasmic staining 
indicates presence of BVDV (Figure 3.7). Positive staining for BVDV infection 
was achieved for mDCs from 2 out of 3 animals. A result from the third repeat 
could not be determined due to staining difficulties. As a positive control, results 
of MDBK-cells infected with either strain are shown for comparative reasons.  
 
A 
 
 
MDBK-cells, 
Ho916ncp 
 
48 
 
 
B 
 
 
 C 
 
 
D 
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mDCs, 
NADLcp 
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Figure 3.7 Representative results from IPX staining determined by light microscopy, 
magnification 100x (Motic AE20 binocular inverted microscope) A) and B) MDBK-cells 
infected with Ho916ncp and Ky1203 respectively. Infection of MDBK-cells was included 
to generate expected positive staining results as these cells are known to be susceptible to 
BVDV. C) Stained uninfected mDCs as a negative control D) mDCs, infected with NADL, 
a BVDVcp strain frequently used in the lab as a positive staining control. E) mDCs 
infected with Ho916ncp MOI 0.1, F) mDCs infected with Ky1203ncp, MOI 0.1. 
 
3.4 Detection of IFNα/β production from stimulated MDBKt2-cells 
MDBKt2-cells were employed to detect IFNα/β in culture supernatants by a CAT-
enzyme reporter gene assay described in section 2.6. Due to the possible 
remaining presence of IFNα/β stimulating ligands after 48 hrs with mDCs an 
mDCs, 
Ho916ncp 
 
mDCs, 
Ky1203ncp 
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experiment was designed to assess the ability of MBDKt2-cells to induce IFNα/β 
directly. MBDKt2-cells were therefore directly stimulated with IFNα/β-inducing 
ligands (Table 2.2) and virus at a MOI of 0.1 and 0.01. An IFNα/β response was 
observed from poly(I:C) stimulated cells only (Figure 3.8).  
 
Figure 3.8 Histogram showing production of IFNα/β in from MDBKt2-cells in response 
to stimulation with ligands and virus as described in section 2.5. TCM: tissue culture 
media (Appendix 1 MDBKt2 growth media), 2336: CpG2336, 2243: CpG2243 scrambled 
control sequence, PIC: poly(I:C), Ho916: Ho916ncp, Ky1203: Ky1203ncp. Details for 
stimulation ligands are described in table 2.2.  
 
Since MDBKt2-cells express TLR3, the response to the synthetic TLR3-ligand 
poly(I:C) is not surprising and has to be taken into consideration when analyzing 
IFNα/β data from stimulated mDCs. However, no production of IFNα/β in 
response to stimulation with Ho916ncp, Ky1203ncp or any other IFNα/β-inducing 
ligand could be detected by this test.   
 
3.5 Detection of IFNα/β production from stimulated mDCs 
mDCs from 3 animals were stimulated with Ho916ncp and Ky1203ncp at a MOI 
of 0.1 and control ligands as described in section 2.6. Supernatants from 
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stimulated cells were analysed for presence of IFNα/β. The results were largely 
consistent, high IFNα/β levels were only generated from stimulation with the 
positive control ligand poly(I:C) as can be seen in Figure 3.9 A showing pooled 
data from the three animals. A low level of IFNα/β compared with the response to 
poly(I:C) was however detected from 1 animal when stimulated with Ho916ncp 
(Figure 3.9 B). The response to Ho916ncp seen in animal 3 is due to a response 
from only one of the duplicates in the experimental set up. Furthermore, mDCs 
generated from animal 2 seemed to respond to the mock controls, but not to any 
ligand or either virus (Figure 3.9 B). 
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Figure 3.9 Histogram showing production of IFNα/β in from mDCs cells in response to 
stimulation with ligands and virus as described in section 2.6. TCM: tissue culture media 
(Appendix 1, mDC media), 2336: CpG2336, 2243: CpG2243, PIC: poly(I:C), Ho916: 
Ho916ncp, Ky1203: Ky1203ncp. Details for stimulation ligands are described in Table 
2.2. A) Mean values for IFNα/β production from 3 individual experiments. B) Individual 
data for animal 1, 2 and 3 only showing IFNα/β production in response to stimulation 
with Ho916ncp, Ky1203ncp and respective mock. 
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3.6 Western blot for IRF3 and IRF7 
The results shown in Figure 3.9 indicate the possibility that mDCs may respond to 
at least Ho916ncp with the production of IFNα/β. To further investigate the 
IFNα/β response in mDCs stimulated with Ho916ncp and Ky1203ncp, protein 
expression of IRF3 and IRF7 was analysed by WB for animal 2 and 3.  
Bands of the expected size for IRF3 (about 50 kDa, Appendix 4) were detected in 
both animals and can be seen as a doublet (as described by others (La Rocca et al 
2005)) (Figure 3.10 A, lane 1, 3, 4, 5, 6 and 8). The relative staining intensity of 
these bands were notably strong in protein extracts from mDCs stimulated with 
Ho916ncp (Figure 3.10 A lane 5) and faint from mDCs stimulated with poly(I:C) 
and Ky1203ncp (Figure 3.10 A lane 2 and 7). A band of the expected size for 
IRF7 (about 54 kDa (Swiss-Prot Acc. No. Q92985)) was only detected for animal 
2 in mDCs stimulated with Ho916ncp (Figure 3.11 A lane 5).  
Despite the fact that all samples were adjusted to the same protein-concentration, 
bands for the loading control β-actin (about 40 kDa, Appendix 4) were 
remarkably fainter for mDC protein extract treated with either poly(I:C), Ho916 
or Ky1203ncp (Figure 3.10 B and 3.11 B lane 2, 5, 7). 
 
   A 
 B 
 
Figure 3.10 Results from Western blot analysis of IRF3 and β-actin representative for 
animal 2 and 3. A) Protein extracts from stimulated mDCs probed for IRF3, B) The 
membrane was stripped and re-probed for β-actin to ensure that the same amount of 
protein was loaded in each well. 
 
  A 
 B 
 
Figure 3.11 Results from Western blot analysis of IRF7 and β-actin for animal 2. A) 
Protein extracts from stimulated mDCs probed for IRF7, B) The membrane was stripped 
and re-probed for β-actin to ensure that the same amount of protein was loaded in each 
well. 
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3.7 qPCR for IL-10 and IL-12 
A preliminary study of how infection with Ho916ncp and Ky1203ncp affect 
expression of the cytokines IL-10 and IL-12 in mDCs was performed using 
TaqMan®qPCR techonolgy for relative quantification of mRNA expression 
levels.  
A relative standard curve method was used to quantify expression of targeted 
genes IL-10 and IL-12 and the endogenous control genes GADPH and RPLPO. 
No data was obtained from IL-12 due to contamination of no template controls.  
 
Figure 3.12 Results from qPCR for the housekeeping gene RPLPO displayed as a dot plot 
diagram showing mean cDNA copy numbers from triplicates of each condition. 
MockHo916: mock Ho916ncp, MockKy1203: mock Ky1203ncp. Error bars represent 
standard deviations(SD).  
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Figure 3.13 Results from qPCR for the housekeeping gene GADPH displayed as a dot 
plot diagram showing mean cDNA copy numbers from triplicates of each condition. 
MockHo916: mock Ho916ncp, MockKy1203: mock Ky1203ncp. Error bars represent 
standard deviations (SD).  
 
Figure 3.14 Results from qPCR for IL-10 displayed as a dot plot diagram showing mean 
cDNA copy numbers from triplicates of each condition. MockHo916: mock Ho916ncp, 
MockKy1203: mock Ky1203ncp.  Error bars represent standard deviations (SD). cDNA 
copy numbers could only be determined in one of the triplicates for Animal 1 mock 
Ho916ncp and mock Ky1203ncp, hence absence of error bars.  
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Figure 3.15 Dot plot showing mean quantities of IL-10 cDNA normalised to mean 
quantities of GADPH to correct results skewed by differing amounts of input cDNA. 
MockHo916: mock Ho916ncp, MockKy1203: mock Ky1203ncp. Error bars represent 
standard deviations. cDNA copy numbers could only be determined in one of the 
triplicates for Animal 1 mock Ho916ncp and mock Ky1203ncp, hence absence of error 
bars.  
 
Any relative difference in mRNA expression levels of IL-10 between mDCs 
stimulated with Ho916ncp compared with Ky1203ncp could not be accurately 
assessed due to the high level of variability in the assay. 
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DISCUSSION 
 
Little is known about why clinical signs following transient acute infection with 
BVDVncp type 1 vary between strains. The interaction between a virus and the 
host’s immune system is clearly of great importance for the outcome of infection. 
Thus, it is interesting to investigate how BVDV strains associated with different 
clinical signs influence early immune responses. BVDV has a predilection for 
infecting cells of the immune system including APCs (Sopp et al 1994 and Glew 
et al 2003). DCs are considered the most important APC in vivo due their efficacy 
in stimulating naïve T-cells (Steinmann and Hemmi 2006). The key role of this 
cell type in shaping the subsequent adaptive immune response makes studying 
viral interactions with DCs most important.  
 
4.1 Generation of mDCs 
Due to the small number of circulating DCs, (Averill et al 2007) methods to 
derive DCs from more accessible precursors have been developed. One such 
method is isolating monocytes from peripheral blood and culturing them in the 
presence of IL-4 and GM-CSF to differentiate them into mDCs (Sallusto and 
Lanzavecchia 1994). mDCs generated from monocytes in peripheral blood offers 
a well established in vitro model for DC function (Glew et al 2003, Barnes et al 
2008) and was therefore used in the present study.  
Enrichment of monocytes by sorting CD14
+
 cells from PBMCs did not generate a 
cell population of similar purity as previously achieved in the lab using the same 
technique. The reduction in purity could depend on the microbeads used for the 
sorting process since they had reached the end of their shelf-life. However, even 
though the FSC/SSC analysis presented as a dot plot shows a rather non-
homogenous cell population, a proportion of cells were indeed CD14 positive as 
demonstrated by FITC-CD14 staining. To generate mDCs CD14
+
 cells were 
cultured for 6 days in the presence of rboIL-4 and rboGM-CSF. However, despite 
the fact that low binding plates were used, cells adhering to the plastic could be 
seen by day 1. These cells are most likely monocytes since lymphocytes do not 
adhere when grown in culture. Indeed, another method to enrich monocytes from 
PBMCs is to isolate adherent cells by removing cells in suspension by washing 
(Werling et al 1999). Some contaminating non-adherent cells (different subsets of 
lymphocytes) can therefore be presumed to be lost during the culturing procedure 
which includes exchange of culture media. 
Light microscopy was used to study changes in cell morphology during culturing 
with cytokine enriched medium. The morphology of the majority of cells by day 
6, characterised by a typical large cytoplasm with cytoplasmic protrusions, was 
consistent with previous descriptions of bovine mDC features (Yamakawa 2007).  
High levels of CD14 expression is commonly used as a marker for monocytes. In 
contrast, CD14 expression is considerably lower on mDCs (Beekhuizen et al 
1991, Werling et al 1999, Bajer et al 2003, Yamakawa et al 2008). Consistent 
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with this, FACS analysis regarding CD14 expressions on cells after 6 days in 
culture with rboIL-4 and rboGM-CSF showed reduced CD14 expression 
compared to freshly enriched monocytes. It would have been desirable to have 
analysed a higher and more uniform number of cells but due to the limited amount 
of mDCs recovered this was not possible.  
Taken together, the phenotype of cultured cells analysed by studying morphology 
and CD14 expression is comparable with the phenotype previously described for 
bovine mDCs.  
 
4.2 TLR expression 
Expression of TLRs on mRNA and protein level varies dependent upon the cell 
subset and stimulation. Some TLRs are more ubiquitously expressed whereas 
other TLRs can be restricted to one cell type (Janssens and Beyaert 2003).  
The result from screening mRNA expression of TLRs in mDCs was largely 
consistent between the 3 animals tested but differs somewhat from pre-existing 
data. In contrast to the results in the present study, bovine mDCs have previously 
been reported to express TLR5 but not TLR3 and TLR7 (Werling et al 2006). 
However, little is still known about the regulation of TLR expression. Thus, 
differences described for bovine mDCs may be due to differential exposure to 
factors influencing TLR expression levels, including animal housing, age, breed 
and also differences in how the cells were treated during culturing. It should also 
be kept in mind that the absence of mRNA expression at a certain time point may 
not necessarily indicate that the corresponding protein is not expressed. 
Discrepancy in results for expression of a specific TLR could therefore also be 
explained by a difference in transcription levels for the targeted TLR at the time 
point analysed (D. Werling, personal communication).   
Examining the expression of TLRs at the mRNA level in mDCs aids the 
understanding of how these cells can sense and respond to different pathogens. 
Presence of TLR3, TLR7 and TLR8 in mDCs indicates that viral infection has the 
potential to activate antiviral responses via TLR-dependent signalling pathways.  
 
4.3 Susceptibility to infection  
mDCs were infected with Ho916ncp and Ky1203ncp at a MOI of 0.1 and 
infection detected by IPX staining for BVDV. Positive cytoplasmic staining 
examined by light microscopy was observed in mDCs infected with both 
Ho916ncp and Ky1203ncp. Not all cells were infected as seen in Figure 3.7 and 
no obvious difference between the relative numbers of cells infected was observed 
by visual inspection.  
Due to staining difficulties a result (positive versus negative) could only be read 
from 2 out of 3 repeats. The third repeat had a high level of background staining. 
Cells stained rather intensively could be seen in the periphery of the wells. 
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However, this staining had a less distinct cytoplasmic confinement. This staining 
pattern could be due to inadequate washing of the wells leaving residual 
secondary antibody along the edges. It would have been desirable to repeat the 
study for this animal but due to the time limit this was not an option.  
Anti-BVDV hyperimmune serum is routinely used in the lab for examining 
presence of virus in buffy coat samples by an immunofluorescence assay (IFA) 
analysed by fluorescent microscopy. This method is not more specific since it still 
utilises polyclonal antibodies but the fluorescent staining with a secondary anti-
bovine Cy3 labelled antibody might be easier to read than the brown staining 
generated from IPX. IFA may therefore be a better option than IPX. To reduce 
unspecific staining a method using monoclonal antibodies against a specific viral 
protein could also be employed.  
The results of experimental infection of mDCs with Ho916ncp and Ky1203ncp 
are consistent with previously published data (Glew et al 2003) indicating that 
mDCs are susceptible to BVDVncp infection. It would be interesting to quantify 
and compare the magnitude of infection and viral replication between Ho916ncp 
and Ky1203ncp. A study comparing the level of infection of mDCs between 
BVDV strains belonging to genotype 1 and 2 revealed a higher magnitude of 
infection for the type 2 strain (a field isolated called KE13) (Glew 2000). It is 
possible that this differential ability of BVDV strains of different genotypes to 
infect mDCs also applies to strains within the BVDV 1 group. Theoretically, the 
ability of a strain to infect mDCs at a higher degree could coincide with a greater 
impact on mDC function. To identify a potential difference between BVDVncp 
strains in their capability to infect mDCs, BVDV infected cells could be stained 
with a fluorochrome conjungated antibody followed by flow cytometric analysis 
to compare the relative numbers of cells infected by Ho916ncp and Ky1203cp. To 
investigate any difference in viral replication an assay could be set up where 
mDCs infected with Ho916ncp and Ky1203ncp are lysed, or the supernatant 
collected at set time points p.i. (for example 24, 48, 72 and 96 hrs) with the 
purpose of comparing the virus titre in cell lysates/supernatants from each time 
point.  
Susceptibility of mDCs to BVDV implicates that BVDV has the potential to 
modify the functions of this important immune cell. Infection and dysregulation of 
DC functions has been shown for many viruses able to establish chronic infections 
or with known immunosuppressive effects, for example measles virus (Fugier-
Vivier et al 2005), HCV (Kanto et al 1999, Averill et la 2007) and human 
immunodeficiency virus (Macatonia et al 1990). mDCs infected with BVDVncp 
have however recently been shown not to be compromised in their ability to 
present antigen and induce BVDV specific CD4
+
 and CD8
+
 T-cell proliferation 
(Glew et al 2001). To date, other than IFNα/β, cytokine data from mDCs infected 
with BVDVncp is lacking.  
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4.4 IFNα/β production 
IFNα/β is a key component in the first line of defense against viral infections, 
inducing an anti viral state in cells subject to infection and affecting the 
development of adaptive immunity. Mammalian cells have evolved a number of 
mechanisms whereby viral infection can be sensed and activate cellular signalling 
to stimulate production of IFNα/β, but at the same time many viruses have 
evolved counter mechanisms to subvert these defences (Garcia-Sastre and Brion 
2006).  
Neither Ho916ncp nor Ky1203ncp induced strong production of interferon from 
mDCs. Small amounts of IFNα/β, less than a tenfold of the amount of IFNα/β 
detected for the positive control poly(I:C), were detected from animal 3 in 
response to Ho916ncp and in mock treated cells for animal 2 but only in one of 
the duplicates for each condition (Figure 3.9 B). One possible explanation would 
be a cross-contamination from a sample with poly(I:C) stimulated cells. Care was 
however taken to minimize this risk by setting up the plates with a row of empty 
wells separating each condition. To find out if Ho916ncp does indeed stimulate 
IFNα/β production from mDCs the number of technical as well as biological 
repeats would need to be increased.  
The amount of IFNα/β in cell lysates from mDCs 48 hrs p.i. was analysed by a 
CAT assay (Fray et al 2001). Due to the possible remaining presence of IFNα/β 
stimulating ligands in mDC supernatants, an experiment was designed to assess 
the ability of MBDKt2-cells to induce IFNα/β in response to the ligands. 
MDBKt2-cells did respond to direct stimulation with poly(I:C) but not to any 
other ligand.  
Since some data report rapid degradation of poly(I:C) in serum (De Clercq 1979), 
poly(I:C) was pre-incubated for 48 hrs at 37°C, 5% CO2 in MDBKt2 culture 
media (containing foetal calf serum) before addition to the MDBKt2-cells to 
mimic the conditions for the mDC stimulation assay. The response to poly(I:C) 
was however not affected by this (data not shown).  
The amount of IFNα/β produced from MDBKt2-cells in response to poly(I:C) 
correlates with the amounts registered for mDCs stimulated with poly(I:C). It is 
therefore not possible to determine if any of the IFNα/β detected by the assay 
originated from the mDCs or was in fact due to poly(I:C) in the supernatant from 
mDC cultures. A well designed positive control is of particular importance when 
results are negative as in this case. However, since WB data confirm mDC 
responsiveness to viral infection and the CAT-ELISA did pick up presence of 
interferon from poly(I:C) stimulation, the negative results for IFNα/β production 
from mDCs stimulated with Ho916ncp and Ky1203ncp can be regarded as real. It 
is therefore crucial for subsequent experiments to identify a positive control which 
induces IFNα/β in mDCs but not in MDBKt2-cells. Such a control could be based 
on the differences in PRR expression between mDC and MDBKt2-cells, which 
seem to lack TLR7 and TLR8 expression. Another approach would be to choose a 
different cell line for transfection with the plasmid expressing the human Mx 
promoter linked to the CAT reporter gene (e.g. human embryonic kidney cells 
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which have a very limited TLR expression). Even so, in both cases it is not known 
whether other intracellular PRRs may compensate for a lack of TLR expression. 
However, the most promising alternative would be the development of an IFNα/β 
ELISA to directly analyse IFNα/β production in the supernatants.  
The lack of IFNα/β production from BVDVncp stimulated mDCs is consistent 
with previously published results (Glew et al 2003). Since mDCs have been 
shown to be susceptible to infection and to express TLRs capable of recognising 
viral nucleic acids (TLR3, 7 and 8), the lack of IFNα/β can be presumed to depend 
on the virus actively evading TLR-dependent as well as TLR-independent 
induction of, or an active suppression of IFNα/β production. Several viruses 
belonging to the Flavivridae family (CSFV, WNV and HCV) are known to 
interfere with the IFNα/β response by affecting the functions of IRF3, a 
transcription factor pivotal for inducing IFNα/β production (Baigent et al 2002, 
Fredricksen et al 2004, La Rocca et al 2005, Li et al 2005, Hilton et al 2006). 
Exactly how this effect is mediated for BVDVncp is not known, but inhibition of 
IFNα/β has been shown to depend on proteins coded by the viral Erns and Npro 
genes (Meyers et al 2007). The product of E
rns
 is a secreted glycoprotein with the 
ability to bind and degrade dsRNA thereby preventing it from activating dsRNA-
induced signalling (Iqbal et al 2004) and the protease encoded by N
pro
 has been 
shown to block the function of IRF3 (Hilton et al 2006, Gil et al 2006).  
 
4.5 Regulation of IFNα/β production through IRF3 and IRF7 
IRF3 is a pivotal transcription factor for IFNα/β expression and is constitutively 
expressed in an inactive form. In contrast to IRF3, IRF7 is only expressed at very 
low levels in most cell types (IRF7 expression in pDCs is however constitutively 
high) but is induced by IFNα/β or TNFα. IRF3 and IRF7 are activated by 
phosphorylation, an event induced by signalling through TLRs recognising viral 
nucleic acid or the cytosolic dsRNA sensors RIG-I and MDA5 (Figure 1.4 and 
1.5). Upon activation IRF3 and IRF7 forms homo- or heterodimers and 
translocate to the nucleus where they bind DNA. IRF3 is only able to stimulate 
expression of a limited number of type I IFN genes whereas IRF7 induces 
expression of a broader spectrum of type I IFN isotypes (Lin et al 1998, Paun A. 
and Pitha P. M. 2007). To further investigate how Ho916ncp and Ky1203ncp 
interact with the IFNα/β response in mDCs protein levels of IRF3 and IRF7 were 
investigated by WB.  
The results in Figure 3.10 A and 3.11 A show a difference in IRF3 and IRF7 
protein concentration after incubation of mDC with either Ho916ncp or 
Ky1203ncp. WB results from mDCs treated with Ho916ncp show intense bands 
of the correct sizes for IRF3 and IRF7 compared to Ky1203ncp and controls.  
The high protein levels of IRF3 in mDCs stimulated with Ho916ncp indicating 
cytoplasmic or nuclear accumulation could be due to a specific effect of 
Ho916ncp or be dependent on a difference in kinetics between the strains, with 
Ky1203ncp causing the same accumulation at another time point. Based on this a 
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time course study of IRF3 protein levels in mDCs infected with Ho916ncp and 
Ky1203ncp should be undertaken. 
In contrast to the results obtained from mDCs stimulated with Ho916ncp, others 
have demonstrated a gradual decrease in IRF3 protein levels (inline with results 
for Ky1203ncp in the present study) in calf testis cells from 6 hrs to 72 hrs p.i. 
(Hilton et al 2006) with the BVDVncp strain pe515. The protein level of IRF3 
was not shown to be upregulated at any time point in this study. 
However, the turnover of IRF3 could be different in mDCs in response to 
BVDVncp infection than in cells previously studied. A study comparing the effect 
of Newcastle virus infection on IRF3 and IRF7 protein stability in immortalized 
embryo fibroblasts and lymphoid tissue (thymus and spleen) from mice show a 
decrease in IRF3 and IRF7 stability in the fibroblasts whereas IRF7 protein 
stability was increased (shown to be partly IFNα/β-independent) in lymphoid 
tissue and IRF3 stability was unaffected (Parkash and Levy 2006). This suggests a 
potential difference in the affect of viral infection on IRF3 and IRF7 turnover 
between different cell types.   
It would therefore be interesting to perform a parallel time course study for IRF 3 
in non-immune cells infected with Ho916ncp and Ky1203ncp to see if the effect 
on IRF3 levels is a feature of mDCs. 
The decrease in IRF3 has been suggested to be a part of the mechanism whereby 
BVDVncp blocks IRF3 function. N
pro
 has been shown to enhance proteosomal 
degradation of IRF3 and to inhibit IRF3 from binding DNA. Published data is 
however inconsistent regarding the latter of these two effects (Baigent et al 2002, 
Hilton et al 2006, Chen et al 2007). In view of the fact that no considerable 
amounts of IFNα/β could be detected in mDC supernatants 48 hrs p.i. with 
Ho916ncp despite high IRF3 protein levels, degradation of IRF3 is unlikely to be 
the only means whereby IFNα/β production is inhibited by this BVDV strain. 
In conclusion, the data of the present study indicate that BVDVncp may interact 
in more than one way with the IRF3 signalling pathway, leading even to its 
stabilisation and that this interaction may depend on cell type and/or strain of 
BVDVncp studied. 
IRF7 expression is normally very low in most cell types (Paun A. and Pitha P. M. 
2007) and accordingly no IRF7 was detected in stimulated mDCs with one 
exception; mDCs stimulated with Ho916ncp from animal 2. Since IRF7 
expression is induced by IFNα/β a possible explanation for this could be that 
Ho916ncp does stimulate production of IFNα/β but at levels too low to allow 
detection by the CAT-ELISA used. However, if this was the case one would 
expect IRF7 expression in animal 3 for which a small amount IFNα/β indeed was 
detected (Figure 3.9B) but no IRF7 expression was detected in these mDCs. Due 
to differences in results between animal 2 and 3 the effect of Ho916ncp on IRF7 
is uncertain and the experiment should be repeated, ideally coupled with a more 
sensitive IFNα/β assay. 
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β-actin was used as a loading control to visualise that the same amount of protein 
was loaded in each well, but the WB results showed variable band-intensities, as 
can be seen in Figure 3.10 B and 3.11 B. Interestingly, lower levels of β-actin 
were present in samples generated from mDCs treated with either poly(I:C), 
Ho916ncp and Ky1203ncp. These discrepancies can potentially be explained 
through either loading errors or an effect of these three agents on β-actin protein 
levels. Whereas the first effect potentially can be excluded, as all samples were 
analysed and adjusted to the same concentration, the second possibility can only 
be excluded through use of another loading control with stable protein levels in all 
conditions. It is striking however that poly(I:C), Ho916ncp and Ky1203ncp all 
share the potential to activate cellular responses to dsRNA. Recently, poly(I:C) 
has been shown to induce IFNα/β-induced apoptosis in bovine turbinate cells 
(Schweizer and Peterhans 2001), which potentially could explain the reduced β-
actin levels seen. In contrast, BVDVncp strains have been shown to protect cells 
from IFNα/β-mediated apoptosis induced by dsRNA dependent signalling 
(Schweizer and Peterhans 2001). Moreover, no notable amount of IFNα/β was 
detected from mDCs stimulated with Ho916ncp and Ky1203ncp. Thus, the 
reduced β-actin content in samples prepared from mDC incubated with either 
BVDVncp strain in present study can not be explained with cellular apoptosis 
induced by IFNα/β.  
Another possibility would be an IFNα/β-mediated down regulation of protein 
expression caused by autocrine actions of IFNα/β produced by stimulated mDCs. 
A IFNα/β response was however only detected for poly(I:C). However, it cannot 
be excluded that mDCs stimulated with Ho916ncp and Ky1203ncp did induce 
IFNα/β at levels at levels too low to allow detection by the IFNα/β detection assay 
used. The only possibility to explore this further would be by using an assay with 
a higher sensitivity compared to the CAT-ELISA used in the present study.  
Even if β-actin levels are considered as a true indicator of the amount protein 
loaded, the increase of IRF3 and IRF7 in mDCs stimulated with Ho916ncp is still 
convincing since the amount of protein seems lower compared to mock infected 
mDCs. The apparent decrease in IRF3 in Ky is however more uncertain since total 
protein levels also appear lower. Another loading control for which the protein 
expression level is stable in all conditions has to be employed to asses these 
results.  
 
4.6 IL-10 and IL-12 
IL-10 and IL-12 are two cytokines secreted by mDCs which have important 
effects on the developing adaptive immune response. IL-10 supports the 
development of a Th2-response, leading potentially to an increased humoral 
response. Furthermore, IL-10 impedes the development of a Th1-type of response 
by blocking IL-12 supported IFNγ production, as well as down regulates 
production of proinflammatory cytokines such as TNF-α, IL-1 and IL-6. IL-10 
also inhibits APC maturation (Dumoutier and Renauld 2002). IL-12 is a 
heterodimeric cytokine composed of the subunits p35 and p40 with a key role in 
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the development of Th1-responses by increasing production of cytokines such as 
IFNγ (Airoldi et al 2002). To date, no data are available regarding the effect of 
BVDVncp on expression of IL-10 and IL-12.  
Unfortunately no reliable data were obtained in the present study to assess the 
effect of BVDVncp on relative mRNA expression levels for IL-10 and IL-12 by 
qPCR. Neither of the BVDVncp strains seems to induce IL-10 mRNA expression 
levels but due to the great assay variability, these results are highly questionable.  
The no template control for IL-12 was contaminated and gave a signal higher than 
the signal detected for several samples. The experiment is therefore invalid and 
has to be repeated taking greater care to avoid contamination. The variation 
between triplicates in all parametes analysed (IL-10, IL-12, GADPH, RPLPO) 
was also greater than acceptable. Here, identical triplicates should have a CT SD 
<0.3 according to manufacturer’s guide (Applied Biosystems, USA). 
Undetermined and variable values suggest lack of/variable amounts of cDNA 
template or failure of the PCR reaction to proceed due to presence of inhibitory 
factors. Though possible to reduce, inhibitory factors are inherently difficult to 
eliminate completely (Nolan et al 2006 a). Pipetting accuracy can however be 
increased by frequent calibration of pipettes, practise and by increasing the 
volumes pipetted.  
To acquire accurate relative quantification of the cDNA target between conditions 
the quantity of the targeted cDNA must be normalised to correct for potential 
differences in total cDNA amount. One way of doing this is by normalising target 
cDNA levels to the levels of a stable endogenous control gene (commonly 
referred to as housekeeping genes). The quantity of these should be relative to the 
input of cDNA and hence not be affected by differences in treatment between 
conditions. Appropriate endogenous controls must therefore be selected and tested 
for each study (Nolan et al 2006 b). Stability of GADPH and RPLPO had not 
been tested in advance for this specific study and expression were found to be 
highly variable between animals and conditions. However, since levels of 
GADPH and RPLPO expression are strongly variable between the two animals 
for the same condition (Figure 3.12, 3.13), the main determinant for variability in 
expression levels might not be the treatment, but may be due to different amounts 
of cDNA. In an attempt to investigate this, the cDNA concentration was re-
evaluated using the NanoDrop
®
 ND-1000 Spectrophotometer as well as the 
Eppendorf Biophotometer. Results (Appendix 3) were quite variable between 
samples compared to the expected and originally adjusted concentration of 100 ng 
μl-1. 
In conclusion the experiment regarding the impact of a BVDVncp infection on 
cytokine expression of mDC must be repeated with appropriate stable reference 
genes, more uniform amounts of cDNA  and avoiding contamination of samples. 
Since qPCR is an extremely sensitive technique relying on many steps which can 
create variability a good normalisation strategy must be followed and results 
should ideally be backed up by another assay, such as ELISAs for IL-10 and IL-
12 quantifying protein levels of each cytokine in the supernatant.  
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4.7 Finial conclusions and future work 
The aim of this project was to compare cytokine production from bovine mDCs 
stimulated with the BVDVncp type 1 strains Ho916ncp and Ky1203ncp with the 
hypothesis that these two strains associated with different clinical outcomes would 
also differ in the cytokine response they induce from mDCs. 
mDCs did not produce any notably levels IFNα/β at 48hrs p.i. in response to 
Ho916ncp and Ky1203ncp and hence no convincing difference between the 
viruses could be demonstrated. This could be due to a viral block of the IFNα/β 
response in mDCs but since only one time point was investigated this can not be 
deduced from this study. The lack of IFNα/β at 48hrs p.i. is consistent with 
existing data (Glew et al 2003) but a time course study is yet to be undertaken.  
A difference between the strains was however detected in their interaction with 
IRF3. mDCs infected with Ho916ncp showed an accumulation of IRF3 in contrast 
to Ky1203ncp which seemed to decrease IRF3 protein levels. This indicates that 
BVDVncp may interact in more than one way with the IRF3 signalling pathway, 
leading even to stabilisation of IRF3 and that this interaction may depend on cell 
type and/or strain of BVDVncp studied. 
The ability of BVDVncp to subvert IFNα/β production is regarded central for 
establishment of persistent infection in the early foetus. In contrast to in vitro 
studies and BVDVncp infection of the early foetus, BVDVncp infection of calves, 
pregnant cows and foetuses in late gestation results in production of IFNα/β 
(Charlston B. et al 2002, Smirnova et al 2008). This contradicting data in vivo and 
in vitro can be explained by the presence of a cell subset in vivo in which 
BVDVncp does not block IFNα/β production. Some studies describe cDCs as an 
important source of IFNα/β in response to viral infection (Diebold et al 2003). 
However, the data presented in this study do not suggest that cDCs are the cell 
type responsible for IFNα/β production in response to BVDV in vivo. The cell 
type responsible for IFNα/β production demonstrated in vivo is more likely the not 
yet fully characterised bovine equivalent of pDCs, as postulated by Brackenbury 
et al 2005. In parallel to experiments performed with mDCs in this study, 
monocytes and lineage negative cells (LIN
-
cells, the potential bovine equivalent 
of pDCs) generated from the same animals have been treated as described for 
mDCs. Indeed, stimulation of LIN
-
cells with BVDVncp did result in production 
of IFNα/β detected at 48 hrs (A. Stalker, personal communication), with 
Ho916ncp inducing more IFNα/β compared to Ky1203ncp.  
BVDVncp strains of high virulence show a more widespread distribution than low 
virulent strains and severe clinical signs have been shown to correlate with a 
higher level of viremia (Walz 2001). It can be hypothesized that the outcome of 
BVDVncp acute infections is determined by a battle between viral spread and the 
host’s immune reaction. An initial difference in how BVDVncp strains interact 
with innate immune functions might therefore be central in determining the 
outcome of infection. The difference in the IFNα/β response between Ho916ncp 
and Ky1203ncp which has been demonstrated for pDCs now asks for further 
characterisation before one can speculate about potential consequence on 
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subsequent immune events and ultimately systemic effects explaining differences 
in clinical signs. 
To begin with, it must be investigated if the difference in amount of IFNα/β from 
pDCs lies in a different capability of the two strains to induce IFNα/β or in 
different kinetics of IFNα/β induction. Is Ky1203ncp able to produce the same 
amount of IFNα/β at another time point and if so, which strain is able to delay 
IFNα/β production in comparison to the other? A time course study needs to be 
undertaken to address these questions and ideally, such a study should be set up 
for a greater number of animals. It would also be interesting to distinguish how 
pDCs differ in their interaction with BVDVncp compared with other cell types, 
enabling them to produce IFNα/β in response to stimulation.  
Finally, with respect to the key role of IFNα/β in the innate antiviral immunity it 
is important to further distinguish the interactions of Ho916ncp and Ky1203ncp 
with the IFNα/β response. Nonetheless, development of an appropriate adaptive 
immune response leading to efficient viral clearance is complex and influenced by 
several factors including interaction of additional cytokines produced by APCs. 
To create a somewhat more complete picture of how BVDVncp strains affect 
early immune events their affect on additional cytokine responses need to be 
investigated. As a first step towards this, IL-10 and IL-12 production from mDCs 
could be reassessed. 
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APPENDIX 1 
 
Buffers and Reagents  
Acid Citrate Dextrose (ACD) 
Citric Acid Monohydrate (Sigma Aldrich UK)      4.0 g 
Sodium Citrate (Sigma Aldrich, UK)      11.3 g 
D(+)-Glucose (Sigma Aldrich, UK)      11.0 g 
Dissolved in 500 ml of ddH20 and sterile filtered (0.22 μm)  
 
D (+) Glucose 0.3 mM stock 
D (+) Glucose (Sigma Aldrich, UK)       29.73 g 
Dissolved in 500ml ddH20 and stored at 4˚C for 1 month. 
 
Ammonium-Chloride Lysis Buffer 
Ammonium Chloride (BDH, UK)      8.29 g 
Potassium Hydrogen Carbonate (Sigma Aldrich, UK)   1.0 g 
EDTA disodium salt (Sigma Aldrich, UK)     0.037 g 
Dissolved in 1 L of ddH20, adjusted to pH 7.2 and sterile filtered (0.22 μm) 
 
PBS/1% BSA 
1X PBS w/o MgCl2 and CaCl2
 
pH 7.2
 
(Sigma Aldrich, UK)   500 ml 
Bovine Serum Albumin Fraction V (PAA, Austria)    5.0 g 
Dissolved together with gentle heating (30˚C) and mixing, sterile filtered (0.22 
μm) 
 
FACSFlow/1%BSA 
BD FACSFlow
TM
 Sheath Fluid (BD Biosciences, UK)    500 ml 
Bovine Serum Albumin Fraction V (PAA, Austria)    5.0 g 
Dissolved together with gentle heating (30˚C) and mixing, sterile filtered (0.22 
μm) 
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mDC differentiation media 
RPMI 1640 + Glutamax I + 25 mM HEPES (Invitrogen, UK)  90 ml 
FBS (PAA, Austria)        10 ml 
Gentamycin (10 mg ml
-1
) (Sigma Aldrich)     0.5 ml 
Sodium Pyruvate (1 M) (Sigma Aldrich)     0.1 ml 
β-mercaptoethanol (0.005 M) (Sigma Aldrich)    0.1 ml 
Recombinant bovine IL-4        1.0 ml 
Recombinant bovine GM-CSF       1.0 ml 
Bovine recombinant GM-CSF and IL-4 were cloned in house and subsequently 
expressed in Chinese hamster overy (CHO) cells produced at the Moredun 
Research Institute, Penicuik, UK and the Institute for Animal Health, Compton, 
UK respectively.    
Prepared in laminar flow in sterile 100ml glass bottles 
 
MDBKt2 Growth Media 
DMEM + Glutamax I + Pyruvate (Invitrogen, UK)     90 ml 
FBS (PAA., Austria)        10 ml  
Pen/Strep (Sigma Aldrich, UK) (5000IU ml
-1
/ 5mg ml
-1
)   2.0 ml   
Blasticidin S HCl (Invitrogen, UK) (10mg ml
-1
)    0.1 ml 
Prepared in laminar flow in sterile 100 ml glass bottles 
 
MDBKt2 Assay Media 
DMEM + Glutamax I + Pyruvate (Invitrogen, UK)     98 ml 
FBS (PAA, Austria)        2.0 ml  
Pen/Strep (Sigma Aldrich, UK) (5000 IU ml
-1
/ 5mg ml
-1
)   2.0 ml   
Blasticidin S HCl (Invitrogen, UK) (10 mg ml
-1
)    0.1 ml 
Prepared in laminar flow in sterile 100 ml glass bottles 
 
10% Growth Medium MDBK 
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MEM (Invitrogen, UK)       500 ml 
FBS (PAA, Austria)        50 ml 
L- Glutmamine (200 mM) (PAA, Austria)     5 ml 
Pen/Strep (5000 IU ml
-1
/5 mg ml
-1
)(Invitrogen, UK)   5 ml 
 
2% Maintenance Medium MDBK  
MEM (Invitrogen, UK)       500 ml 
FBS (PAA, Austria)        5 ml 
L- Glutmamine (200 mM) (PAA, Austria)     5 ml 
Pen/Strep (5000 IU ml
-1
/5 mg ml
-1
)(Invitrogen, UK)   5 ml 
 
PBS-T (0.05%) stock 
10X PBS in ddH20 (Invitrogen, UK)      1000ml 
Tween20         0.5 ml  
 
PBS-T 5%NRS 
500 ml PBS-T stock as above with addition:     
Normal Rabbit Serum (NRS) (Invitrogen, UK)    25 ml 
Aliquoted to 50 ml and stored at -20˚C 
 
PBS/1% BSA/0.1% NaN3 
1X PBS w/o MgCl2 and CaCl2
 
(Sigma Aldrich, UK)    500 ml 
Bovine Serum Albumin Fraction V (PAA, Austria)    5.0 ml 
Sodium Azide (10%) in ddH20 (Sigma Aldrich)    5.0 ml 
BSA dissolved in PBS with gentle heating (30˚C) prior to addition of Sodium 
Azide 
 
5X Laemmli Sample Buffer 
Tris/Glycine Running Buffer 1X (Bio-Rad, UK)    6.25 ml 
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30% Glycerol (Sigma Aldrich, UK)      16.5 ml 
10% SDS (Fluka, Sigma Aldrich, UK)     20 ml 
Β-mercaptoethanol (Sigma Aldrich, UK)     5 ml 
1% Bromophenol Blue (Sigma Aldrich, UK)    1 ml 
 
30% Glycerol 
Glycerol (100%) (Sigma Aldrich)      3 ml 
Molecular Biology Grade H20 (Sigma Aldrich)    7 ml 
 
PBS-T/5% non-fat milk 
10X PBS w/o MgCl2 and CaCl2
 
(Invitrogen, UK)
    
50 ml 
 
ddH20          450 ml 
Non-fat dried milk powder (Marvel, UK)     5 g 
Tween20 (Sigma Aldrich, UK) 
    
      0.25 ml 
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APPENDIX 2 
 
Plasmid details 
TLR1 
Bovine TLR1 full length construct (Accession Number: AY634638) in pCR2.1 
TOPO (Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, 
Compton as part of the Genesis Faraday TLR Consortium. 
TLR2 
Full length bovine TLR2 construct (Accession Number: AY634629) in pCR2.1 
TOPO (Invitrogen, UK) by D. Werling, Royal Veterinary College, UK.   
TLR3 
Full length bovine TLR3 construct (Accession Number: AY821206) in pCR2.1 
TOPO (Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, 
Compton as part of the Genesis Faraday TLR Consortium. 
TLR4 
Full length bovine TLR4 construct (Accession Number: AY634630) in 
pcDNA3.1/V5-his (Invitrogen, UK) by D. Werling, Royal Veterinary College, 
UK.  
TLR5 
Bovine TLR5 full length construct (Accession Number: AY634631) in pCR2.1 
TOPO (Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, 
Compton as part of the Genesis Faraday TLR Consortium. 
TLR6 
Full length bovine TLR6 (Accession Number: AY487803) in pCR2.1 TOPO 
(Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, Compton as 
part of the Genesis Faraday TLR Consortium. 
TLR7 
Bovine TLR7 full construct (Accession Number: AY487802) in pCR2.1 TOPO 
(Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, Compton as 
part of the Genesis Faraday TLR Consortium. 
TLR8 
Bovine TLR8 full length construct (Accession Number: AY642125) in pCR2.1 
TOPO (Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, 
Compton as part of the Genesis Faraday TLR Consortium. 
TLR9 
Full length bovine TLR9 (Accession Number: AY859726) in modified pASK-
IBA1 (893plasmid) from Hans-Martin Seyfert.  
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TLR10 
Full length bovine TLR10 (Accession Number: AY634632) in pCR2.1 TOPO 
(Invitrogen, UK) from Tracey Coffey, Institute of Animal Health, Compton as 
part of the Genesis Faraday TLR Consortium. 
β-actin  
Bovine β-actin full length construct (Accession Number: AY141970) in pCIneo 
(Promega, UK) by D. Werling, Royal Veterinary College, UK.  
5’UTR BVDV 
5’UTR sequence from BVDV type 1 strain NADL (Accession Number: M31182) 
in pGEM-T (Promega, UK) from Carole Thomas, Royal Veterinary College, UK.  
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Plasmid Maps 
pCR2.1 TOPO 
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pcDNA3.1V5-His 
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pGEM-T plasmid 
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pCIneo plasmid 
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APPENDIX 3 
 
Spectrophotometric analysis of cDNA concentrations 
 
 
cDNA concentration (ng μl-1) measured by NanoDrop® ND-1000 
Spectrophotometer (Nandrop) and Eppendorf Biophotometer (Spectrophotometer) 
synthesised from mDCs stimulated with Ho916ncp and Ky1203ncp and 
respective mock (MockHo916ncp and MockKy1203).  
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APPENDIX 4 
 
Datasheets for antibodies used in Western blot for detection of β-actin, IRF3 and 
IRF7.  
 
 
 
 
